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Abstract 
 
The growth and differentiation of bone cells is controlled by various factors which can be 
modulated by heparan sulphates. Here, we investigated the effects of an oversulphated 
”heparin-like” exopolysaccharide (OS-EPS) on bone. We compared the effect of this 
compound with that of a native exopolysaccharide (EPS). Long-term administration of OS-
EPS causes cancellous bone loss in mice due, in part, to an increase in the number of 
osteoclasts lining the trabecular bone surface. No significant difference in cancellous bone 
volume was found between EPS-treated mice and age-matched control mice, underlying the 
importance of sulphatation in trabecular bone loss. However, the mechanism sustaining this 
osteoporosis was unclear. To clarify OS-EPS activities, we investigated the effect of OS-EPS 
in osteogenesis. Our results demonstrated that OS-EPS inhibited osteoclastogenesis in two 
cell models. By surface plasmon resonance technique we revealed that OS-EPS can constitute 
a hetero-molecular complex OS-EPS/RANKL/RANK and that RANK had a higher affinity 
for RANKL pre-incubated with OS-EPS than for RANKL alone which would be in favour of 
an increase in bone resorption.  However, in vitro, OS-EPS inhibit the early steps of osteoclast 
precursor adhesion and therefore inhibits the step of cell fusion. In addition, we showed that 
OS-EPS reduces the proliferation and accelerates osteoblastic differentiation, leading to 
strong inhibition of mineralized nodule formation, which would be in favour of an increase in 
bone resorption. Taken together, these data show different levels of bone resorption regulation 
by exopolysaccharides, most of them leading to proresorptive effects. 
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Introduction 
 
Bone, a specialized connective tissue, is continually remodelled according to 
physiological events. This remodelling results from the activities of many cell lineages 
including mainly osteoblasts, osteocytes and osteoclasts. Their cellular interactions control 
their cellular activities and the bone remodelling intensity. These interactions can be 
established either through a cell–cell contact or by the release of many polypeptidic factors 
and/or their soluble receptor chains (cytokines, growth factors). These factors can act directly 
on osteogenic cells and their precursors to control differentiation, formation and functions 
(e.g. matrix formation, mineralization, resorption) (Kwan Tat et al., 2004). Among these 
factors, proteoglycans (PGs) appear critical for maintaining an appropriate number of 
osteoblasts and osteoclasts by modulating their proliferation and/or differentiation 
(Lamoureux et al., 2007).  
PGs are composed of a core protein with covalently attached glycosaminoglycan 
(GAG) chains. These GAGs, linear polymers of repeated disaccharidic units, are sulphated 
and the number and position of sulphate are extremely variable in sulphated GAG depending 
on the tissular, cellular, and metabolic context, ensuring structural variability of these 
polysaccharides (Bernfield, 1999). These PGs are ubiquitous, being present as cell surface 
molecules anchored in the plasma membrane, as components of the insoluble extracellular 
matrix or as soluble molecules present in extracellular matrix and serum. PGs function in both 
cell–cell and cell–extracellular matrix adhesion and can also act to promote assembly of 
extracellular matrix molecules. Additionally, PGs bind a wide range of bioactive molecules, 
such as growth factors, chemokines, which regulate cell behaviour in normal and pathological 
processes. Thus, PGs or GAGs associated to the cell membrane or resident in the extracellular 
bone matrix regulated the bone growth and remodelling (Ruiz Velasco et al., 2010). 
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The osteoprotegerin (OPG)/Receptor Activator of NF- B (RANK)/RANK Ligand 
(RANKL) molecular triad has been identified as members of a ligand-receptor system that 
directly regulates osteoclast differentiation and osteolysis (Simonet et al, 1997). While 
RANKL is a powerful inducer of bone resorption through its interaction with RANK (Kong et 
al., 1999), OPG acts as a decoy receptor for RANKL, thereby strongly inhibiting osteoclast 
differentiation (Yasuda et al., 1998). Any dysregulation of their respective expression leads to 
pathological conditions (Wittrant et al., 2004). OPG contains a heparin-binding domain and 
strongly bind to GAGs with a high affinity (KD: 0.28 nM for heparin) (Theoleyre et al., 2006). 
Therefore, PGs decrease the bioavailability of OPG inducing its internalization (Standal et al., 
2002, Kwan Tat et al., 2006) are involved in OPG-induced chemotaxis of monocytes 
(Mosheimer et al., 2005) and enhance the RANKL  half-life at the cell membrane (Kwan Tat 
et al., 2006). Similarly to OPG, PGs interact with RANKL. For example, Shinmyouzu et al. 
(2007) showed that dermatan sulphate inhibits the binding of RANK to RANKL and reduce 
the RANKL-induced levels of MAPK signal transduction in osteoclast progenitors, thus 
abolishing osteoclastogenesis. These data demonstrate that PGs must be considered as 
essential co-factors modulating bone remodelling. Thus, PGs are not simply passive structural 
components of cells and extracellular matrices, rather, they are multifunctional molecules that 
regulate cell behaviour by fine tuning the function of many regulatory proteins (Lamoureux, 
2009). 
Heparin demonstrates several kinds of biological activities by binding to various 
extracellular molecules and plays pivotal roles in bone metabolism. However, the role of 
heparin in the biological activity of bone remains unclear. Recently, Ariyoshi et al. (2008) 
showed that heparin, after binding to RANKL, suppressed osteoclastogenesis and inhibited 
the formation of resorption pits induced by RANKL, whereas the other GAGs showed no 
effects. In contrast, Irie et al. (2007) showed that heparin specifically binds to OPG and 
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prevents OPG-mediated inhibition of osteoclastic bone resorption in the coculture of mouse 
bone marrow cells and osteoblasts and demonstrated that heparin enhances osteoclastic bone 
resorption by inhibiting OPG activity. Long-term heparin treatment causes cancellous bone 
loss in rats due in part to an increase in the number of osteoclasts lining the trabecular bone 
surface. However, results from various other groups suggest that GAGs, and in particular 
heparan sulphate (HS) and heparin, are potent co-stimulators of osteogenic signaling 
pathways (Zhao et al, 2006; Jackson et al, 2007; Ling et al, 2010)). Thus, the opportunity 
arises to leverage the stimulatory properties of HS-derived compounds as adjuvants for osteo-
inductive therapies.  
A broad series of polysaccharides has emerged as an important class of bioactive 
products (Franz and Alban, 1995; Bernas, 2003; Mayer and Lehmann, 2001). Polysaccharide-
producing marine microorganisms occur widely in nature in different types of habitat 
(Sutherland, 1996), and some thermophilic and mesophilic polysaccharide-producing strains 
have been isolated from deep-sea hydrothermal vents (Guezennec, 2002; Nichols et al., 
2005). Alteromonas infernus, classified as a non-pathogenic microorganism by the Institut 
Pasteur, secretes a water-soluble acidic heteropolysaccharide (Raguénès et al., 1997). The 
composition of this high-molecular-weight polysaccharide (10
6
 g/mol) differs in 
monosaccharide content and/or ratio and sulphate content (10%) from other polysaccharides 
isolated from deep-sea hydrothermal bacteria and from polysaccharides of other origins. 
Structural characterization has shown that this exopolysaccharide is a highly branched acidic 
heteropolysaccharide composed of neutral sugars (glucose, galactose) and uronic acids 
(glucuronic acid and galacturonic acid) (Roger et al, 2004). The high-molecular-weight 
exopolysaccharide was chemically depolymerised and sulphated, with a view to obtaining a 
bioactive compound compatible with a therapeutic use (Roger et al, 2004). Highly sulphated 
low molecular-weight exopolysaccharide (40% sulphate groups, MW: 24 000, Fig. 1), with 
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uronic acid and sulphate contents comparable to those of heparin, were obtained without 
altering the osidic composition of this polymer (Guezennec et al., 1998). In contrast to the 
exopolysaccharide secreted by Alteromonas infernus, this oversulphated exopolysaccharide 
(OS-EPS) exhibits anticoagulant properties. It is less potent than low-molecular-weight 
heparin and unfractionated heparin (2.5 and 6.5 times, respectively), and should therefore 
carry a lower risk of bleeding (Colliec-Jouault et al., 2001). OS-EPS increases angiogenic 
properties of FGF-2 (Fibroblast growth factors-2) or VEGF (Vascular endothelial growth 
factor), i.e. endothelial cell proliferation and differentiation into vascular tubes; however it 
also inhibits the effect of FGF-2-induced cell migration (Matou et al., 2005). These 
angiogenic properties of OS-EPS are related to its sulphate content because no effect was 
observed with the native low molecular-weight exopolysaccharide (EPS). FGFs play an 
important major role in the control of cell proliferation, differentiation, and survival in several 
tissues including bone (Marie, 2003). Notably, FGF2 was found to promote cell growth and 
osteoblast differentiation in bone marrow-derived mesenchymal cells (Miraoui et al, 2009). In 
addition, FGF2 upregulate the expression of RANKL on rheumatoid arthritis synovial 
fibroblasts (Nakano et al., 2004). However, no data concerning the structure and biological 
activity of these exopolysaccharides on bone cells proliferation and differentiation were 
available until now. To explore its capacity to promote bone resorption or formation, an 
influence of OS-EPS on bone cell proliferation and differentiation was determined. OE-EPS 
was compared with EPS in order to study the effect of sulphate content on the biological 
properties of the exopolysaccharide. 
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Results 
 
OS-EPS inhibits the proliferation of BMSCs during osteoblastic differentiation 
  To study the effect of OS-EPS on osteoblast precursors, we used the bone marrow 
stem cells (BMSCs) model, in which dexamethasone is known to induce osteoblast 
differentiation. Proliferation of BMSCs during osteoblastic differentiation was analyzed in the 
presence of OS-EPS. 25 µg/mL of OS-EPS significantly inhibited cell proliferation (Fig. 2A 
and 2B) in contrast to EPS. To determine whether these effects were due to inhibition of cell 
proliferation and/or induction of cell death, we used time-lapse microscopy to monitor the 
mitosis events. The results demonstrated a 70% inhibition of cell mitosis in the presence of 
25µg/mL of OS-EPS after   48 h of culture as compared to the control (Fig. 2C). To determine 
whether the OS-EPS induced death in BMSCs by apoptosis, Hoechst staining and caspase-3 
activation were investigated. Hoechst staining showed no modification of nuclear morphology 
in the presence of OS-EPS as compared to control cells (data not shown). Concerning the 
caspase-3 activity in BMSCs, the results showed that OS-EPS does not induce any activation 
of caspases (not shown). Flow cytometry of DNA content was performed to identify cell cycle 
perturbations following treatment with OS-EPS over a 48-h period in BMSCs. Although 24 h 
of OS-EPS treatment did not modulate the cell cycle in BMSCs (data not shown), 48 h of OS-
EPS treatment induced a cell cycle arrest in G1 phases (Fig. 2D).  Indeed, the number of cells 
in G1 phases increased from 73 ± 2 to 83 ± 3 % when treated with OS-EPS (Fig. 2D). This 
observation was concomitant with a reduction of cells in S and G2/M phases: 25 ± 3 versus 17 
± 2 % (Fig. 2D). EPS had no effect in any of the experimental conditions, underlying the 
importance of sulphatation in the proliferation. 
 
OS-EPS inhibits mineralized nodule formation in pre-osteoblasts 
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To examine the role of OS-EPS on extracellular matrix mineralization in BMSCs 
cultures, BMSCs were treated for 17 days with OS-EPS, after which mineral was visualized 
by von Kossa staining. As demonstrated in Fig. 3A, OS-EPS dose-dependently inhibited 
mineralization with maximal inhibition occurring at 50 µg/mL. In late BMSCs culture, OS-
EPS reduced the formation of bone nodules. To further understand the mechanism by which 
OS-EPS inhibits mineralization, cultures were treated with 25 µg/mL OS-EPS during days 3–
17. OS-EPS reduced the formation of bone nodules when added in the two first weeks but not 
later (Fig. 3B), suggesting that OS-EPS blocks culture mineralization mainly by adversely 
affecting osteoblast differentiation and matrix deposition during the early matrix assembly 
stage and not by direct binding to hydroxyapatite crystals during the mineralization stage. 
Based on reduced mineralization, it was expected that OS-EPS would reduce expression of 
osteoblastic markers in cells. This study was performed on BMSCs under conditions where 
runt-related transcription factor 2 (Runx2), alkaline phosphatase (ALP) and type I collagen 
expression (Col1 1) were observed by preosteoblast stage, followed by bone sialoprotein 
(BSP) and osteocalcin (OC) by mature osteoblast stage. Unexpectedly, after 17 days of 
treatment, OS-EPS induced BSP and OC in a dose dependent manner (Fig. 3C). In contrast, 
OS-EPS reduced ALP, Runx2 and coll 1 mRNA level in a dose dependent manner (Fig. 3C). 
However, Runx2 was transiently and strongly induced by OS-EPS; it increased after 7 days, 
reached a peak level at 10 days (14 days for the control), and decreased thereafter (Fig 3 C). 
This result clearly demonstrated an effect of OS-EPS on the osteoblastic differentiation. OS-
EPS acted at the early steps of the process by affecting the preosteoblast and accelerating the 
osteoblactic differentiation. 
 
OS-EPS inhibits RANKL-induced osteoclastogenesis in human models  
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CD14
+
 cells are human monocyte cells which can differentiate into tartrate-resistant acid 
phosphatase (TRAP)-positive multinucleated cells in 21 days upon RANKL stimulation. As 
shown in figure 4A, in contrast to EPS, addition of 0,5µg/ml OS-EPS, at the same time that 
RANKL addition, almost completely inhibited RANKL-induced osteoclastogenesis (p<0.01). 
We confirmed this effect in a second model of osteoclastogenesis. RAW 264.7 cells are 
murine monocyte/macrophage cells which can differentiate into TRAP-positive 
multinucleated cells in 5 days upon RANKL stimulation. OS-EPS completely inhibited 
RANKL-induced osteoclastogenesis of RAW 264.7 (results not shown). To better 
characterize the mechanisms by which OS-EPS inhibits osteoclast formation, the effect of 
OS-EPS were assessed at different times of the culture period. When OS-EPS was added 3 
days before RANKL (D-3) to the culture, no osteoclasts were generated after 17 days (Fig. 
4A) and the number of adherent CD14
+
 osteoclast precursors was decreased compared to the 
control condition. To determine whether these effects were due to induction of loss of 
adhesion, the effects of OS-EPS were evaluated by counting viable cells, as assessed by 
trypan blue exclusion. After the adherence of CD14
+
 cells in the wells, these cells were 
incubated with EPS or OS-EPS during 5 days. Blue trypan counting revealed that OS-EPS 
causes a loss of adherence of this type of cells (Fig. 4B). Thus in this culture condition, fewer 
osteoclast precursors adhered to the plastic surface and less osteoclasts were generated in the 
presence of RANKL. The addition of OS-EPS after one week culture step (D7) did not 
completely inhibit osteoclast formation (Figure 4A). OS-EPS acted at two distinct levels of 
osteoclastogenesis: i) at the early steps of the process by affecting and decreasing cell 
adherence and ii) at the end of the osteoclastogenesis process by inhibiting the spreading of 
the preformed osteoclasts. This result clearly demonstrated an effect of OS-EPS on RANKL-
induced osteoclastogenesis. OS-EPS acted at the early steps of the process by affecting and 
decreasing cell adherence. 
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OS-EPS binds to RANKL  
OPG/RANK and RANKL have been identified as members of a ligand-receptor 
system that directly regulates osteoclast differentiation and osteolysis. While RANKL is a 
powerful inducer of bone resorption through its interaction with RANK, OPG is a soluble 
decoy receptor and acts as a strong inhibitor of osteoclastic differentiation. 
Surface plasmon resonance (SPR)-binding assays showed that recombinant full length 
OPG binds immobilized heparin (Theoleyre et al., 2006). To determine the involvement of 
OS-EPS in the binding of OPG, we determined kinetic parameters by injecting different 
concentrations of OS-EPS over immobilized OPG and thus demonstrated a high-affinity OPG 
binding to OS-EPS (dissociation constant KD: 0.22 nM) (Fig. 5). To explore the molecular 
mechanism underlying the effect of OS-EPS on RANKL-induced osteoclastogenesis, we 
investigated the molecular interactions between RANKL and OS-EPS by SPR. Surprisingly, 
OS-EPS was also able to bind to immobilized-RANKL, whereas EPS was not (Fig. 5A). We 
next compared OS-EPS activity to that of heparin, heparan sulphate, chondroitin sulphate and 
dermatan sulphate. None of the GAGs analyzed were able to bind to RANKL, with the 
exception of OS-EPS (Fig. 5A). Furthermore, using a single cycle kinetic assay, the KD of 
OS-EPS for RANKL was 91 pM (Fig. 5).  
Since RANKL is the natural ligand of RANK, we wondered whether OS-EPS could 
inhibit the complex RANKL–RANK present at the osteoclast membrane. We investigated the 
molecular interactions between OS-EPS, RANKL and RANK by SPR technique. We 
confirmed that RANK or RANKL bound to immobilized RANKL or immobilized RANK, 
respectively (Fig. 5B and 5C). While, in our conditions, OS-EPS did not bind to immobilized 
RANK (Fig. 5C), it bound to the preformed RANKL/RANK complex (Fig. 5B) thereby 
forming a ternary complex OS-EPS/RANKL/RANK. In addition, the pre-incubation of OS-
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EPS (30 min at room temperature) with RANK or RANKL did not inhibit the capacity of OS-
EPS to further bind to the preformed ternary complex OS-EPS/RANKL/RANK (data not 
shown). However, sensorgrams with RANKL, pre-incubated or not with OS-EPS, 
immobilized on the surface of a CM5 sensor chip revealed different binding response units for 
RANK (Fig. 5B). To determine the biophysical binding parameters for the ternary complex 
interactions, real-time SPR spectroscopy was performed (Fig. 6). Surprisingly, the kinetic 
study shows a significant increase of the association rate of RANK to RANKL pre-incubated 
with OS-EPS facilitating the complex formation. RANK had higher affinity for RANKL pre-
incubated with OS-EPS surface sensor chips than for RANKL surface sensor chips (> 2-fold). 
This result would be in favour of an increase in bone resorption which has not been observed 
during the study of osteoclastogenesis (Fig. 4).  
RANKL is not only a ligand for RANK but also acts as ligand for the decoy receptor 
OPG. To determine whether or not OS-EPS could affect the complex OPG/RANKL, RANKL 
has been immobilized on a sensor chip, and the capacity of OS-EPS to bind to complex 
OPG/RANKL was analyzed. Similar to the RANKL/RANK complex, OS-EPS is able to bind 
to a preformed OPG–RANKL complex (Fig. 5D and 5E) forming another ternary complex 
OS-EPS/RANKL/OPG. Also, the pre-incubation of OS-EPS (30 min at room temperature) 
with OPG or RANKL did not inhibit the capacity of OS-EPS to further bind to the preformed 
ternary complex OS-EPS/RANKL/OPG (data not shown). However, no modification of the 
kinetic parameters of the interaction of the OPG to RANKL pre-incubated with OS-EPS was 
observed. 
 
OS-EPS induces trabecular bone loss.  
During the 28 days of this study all of the mice from the different treatment groups 
(OS-EPS, EPS and heparin-treated) gained weight. No significant differences with respect to 
13 
 
weight gain were found between those mice treated with either OS-EPS or EPS or heparin or 
age-matched controls. However, at the femur level, micro-CT scanner analysis revealed that 
the mouse femur was characterized by large remodelling activities as compared to control 
femurs (Fig.7A). Thus, OS-EPS produced a reduction in cancellous bone volume when 
compared with control. The effect of OS-EPS on cancellous bone was similar to that of our 
positive control (heparin). OS-EPS did not modify the cortical bone volume (data not shown) 
but significantly reduced the trabecular bone volume (p< 0.01; Fig.7A). The trabecular 
number (Tb.N) was significantly reduced by OS-EPS (p<0.05), whereas the trabecular space 
(Tb.Sp) increased (p<0.05). Trabecular thickness (Tb.Th) was not significantly altered (Fig. 
7). However, no significant difference in cancellous bone volume (BV/TV) was found 
between EPS-treated mice and age-matched control mice, underlying the importance of 
sulphatation in trabecular bone loss. 
Histologic sections were stained with TRAP or ALP to quantify osteoclast or 
osteoblast surface-based data, respectively. Figure 7B shows that the parameter of osteoblast 
surface was not significantly different when comparing OS-EPS or EPS-treated mice and age-
matched controls. In contrast, OS-EPS produced an increase in the percentage of cancellous 
bone covered by osteoclasts. Whereas mice given 6 mg/kg OS-EPS showed a 125% ± 23% 
(p<0.05) increase in osteoclast surface, osteoclast surface was unaffected by treatment with 
EPS (Fig. 7B). 
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Discussion 
 
In the present study, we have shown that long-term administration of OS-EPS, a 
`heparin-like' component (containing uronic acid and sulphate contents comparable to those 
of heparin) with `heparin-like' activity (anticoagulant properties), causes cancellous bone loss 
in mice due, in part, to an increase in the number of osteoclasts lining the trabecular bone 
surface. Our results are therefore similar to results published many years ago, in which long-
term administration of heparin was shown to lead to the development of osteoporosis (Muir et 
al., 1996). Similarly, Barbour et al.  (1994) showed that 36% of pregnant women undergoing 
long-term heparin treatment had a 10% reduction in femoral bone mineral density. Both 
heparin (Muir et al., 1996; Muir et al., 1997, Rajgopal et al., 2008) and OS-EPS increase the 
process of bone resorption. Although, heparin and OS-EPS has similar effects on osteoclast 
number, heparin was found to decrease osteoblast number (Muir et al., 1996; Muir et al., 
1997, Rajgopal et al., 2008), whereas OS-EPS has no effect. These effects resulting in bone 
loss begin early in the course of OS-EPS treatment (data not shown). However, the 
mechanism sustaining osteoporosis was unclear and it was difficult to determine if these 
effects on bone resorption were due to the direct effect of OS-EPS on osteoclasts or indirectly 
via its osteoblast activity. 
GAGs exhibit several kinds of biological activities by binding to various extracellular 
molecules and play a pivotal roles in bone metabolism. An indirect proof of heparan sulphate 
proteoglycans (HSPGs) involvement in osteoclast functions was recently shown in a 
publication that demonstrated that heparanase, a HS-degrading endoglycosidase expressed in 
osteoblastic cells, stimulates bone formation and bone mass (Kram et al., 2006). The effect of 
GAGs on osteoclastogenesis is controversial. For example, Ariyoshi et al.  (2008) and 
Shinmyouzu et al. (2007) showed an inhibition of osteoclastogenesis after a direct interaction 
15 
 
of GAGs with RANKL. In contrast, Irie et al. (2007) showed a stimulation of osteoclastic 
bone resorption by inhibiting OPG activity. Our results clearly demonstrated that OS-EPS 
inhibited osteoclastogenesis in two systems tested. Furthermore, we demonstrated the 
importance of the sulphation of the exopolysaccharide in their inhibitory effect. Sulphation 
also plays a key role in GAGs biological activities as revealed by the present work. Sulphated 
polysaccharides enhance the biological activity of both homodimers and heterodimers of bone 
morphogenetic protein (BMP) by continuously serving the ligands to their signalling receptors 
expressed on cell membranes, similar to oversulphated chondroitine sulphate that binds to 
BMP-4 and enhances osteoblast differentiation (Miyazaki et al., 2008). Sulphation has clearly 
been shown to participate in to the control of cell biology. Kumarasuriyar et al. (2009) 
showed that the chlorate-induced-desulphation of GAGs expressed by MG63 cells delayed in 
vitro osteogenesis. In addition, sulphation strongly modulates the interaction of GAGs with 
proteins such as growth factors or enzymes (Lamoureux et al., 2007; Gallagher, 2006).  
However, the question remains of how we can explain the strong discrepancies 
between the in vivo and in vitro results.  In this context, we first analyzed the interaction of 
OS-EPS with the OPG/RANK/RANKL molecular triad and the effect of OS-EPS on adhesion 
of osteoclast precursors. Here, we clearly showed that OS-EPS can constitute a hetero-
molecular complex (OS-EPS /RANKL/RANK or OS-EPS/RANKL/OPG) as demonstrated by 
surface plasmon resonance technique and that RANK possesses a higher affinity for RANKL 
pre-incubated with OS-EPS than for RANKL alone. Contrarily, OS-EPS does not interfere in 
the binding of RANKL by OPG. These results also revealed that RANKL had higher affinity 
for OS-EPS (KD = 91 pM) than for OPG (KD = 0.27 nM, Kwan Tat et al, 2006). In 
conclusion, the preferential binding of RANKL to OS-EPS is able to facilitate the binary OS-
EPS/RANKL complex formation, which, in turn, may facilitate the ternary OS-
EPS/RANKL/RANK complex formation, which would be in favour of an increase of the bone 
16 
 
resorption. Secondly, we analyzed the effects of OS-EPS on adhesion of osteoclast precursors, 
demonstrating a sequential effect of OS-EPS on RANKL-induced osteoclastogenesis. OS-
EPS inhibit the early step of osteoclast precursor adhesion and consequently inhibits the step 
of cell fusion. The alteration of cell adhesion and morphology prevents the cell fusion of 
osteoclast precursors and blocks osteoclast resorption which is particularly sensitive to cell 
morphology to develop their brush border (Rousselle and Heymann, 2002). 
Our data are in favour of a direct inhibitory activity of OS-EPS on osteoclastogenesis 
and the effect observed in vivo may be explained by its effects on the bone osteoblast 
compartment and then by the dysregulation of the balance between osteoblasts and osteoclasts 
or by a slow-down of bone remodeling. The rate of bone formation is dependent on the 
commitment and replication of osteoprogenitor cells, their differentiation into functional 
osteoblasts and the life span of mature osteoblasts. Cells are committed to the osteoblast 
lineage by induction of the transcription factor Runx2 (Karsenty, 2001). This osteoblast 
differentiation is regulated by the actions of systemic and local signalling factors. Among 
these factors are FGFs, a family of polypeptides that control the proliferation and 
differentiation of osteoblast cell (Xiao et al., 2010). Thus, FGF2 is a powerful promoter of 
bone growth, enhancing mineralized nodule formation (Downey et al., 2009). This effect is 
mediated via HSPGs that coordinate the interaction of FGFs with their high-affinity tyrosine 
kinase receptors, the FGFRs (Eswarakumar et al., 2005). The interaction of PGs with FGFs 
provides a physiological mechanism for regulation of FGF signalling, FGFR1, and the 
extracellular signal-regulated kinase pathway. Furthermore, osteoclast differentiation and 
activity are regulated by GAGs at different levels, as revealed in previous studies. FGF-2 
induces, after the binding to HS, the expression of RANKL and osteoclast maturation by 
rheumatoid synovial fibroblasts. FGF-2 not only augments the proliferation of rheumatoid 
synovial fibroblasts, but is also involved in osteoclast maturation, which leads to bone 
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destruction in rheumatoid arthritis (Nakano et al., 2004 Matou et al. (2005) showed the 
binding of OS-EPS to FGF-2, therefore we hypothesize that FGF-2 can induce bone 
resorption after binding to OS-EPS. 
Osteoblastic cells produce a complex extracellular matrix composed of a mixture of 
PGs, collagens and non-collagenous proteins. The interaction of PGs with matrix effector 
macromolecules via either their GAG chains or their protein core is critical in regulating a 
variety of cellular events. Alterations in the structural composition of the GAG/PG 
components of the extracellular matrix may have important consequences on cell proliferation 
and/or differentiation. Recently, Haupt et al. (2009) demonstrated the dependence of 
osteogenesis on specific HS chains, in particular those associated with glypican-3. The 
differentiating osteoblast-committed cells produce a homogenous HS species, which 
correlates with an increase in the HSPG glypican-3. Abrogation of glypican-3 reduces the 
expression of the osteogenic transcription factor Runx2. The data demonstrate tight linkage 
between HS modification and progression of osteogenic precursors through their 
developmental program.  
Our results showed that (1) OS-EPS reduces expression of ALP, coll I, Runx2 
(preosteoblast stage) in BMSCs cells and enhances OC and BSP mature osteoblast stage); (2) 
exogenous application of OS-EPS to cultures of primary BMSCs during in vitro 
differentiation completely blocks BMSC mineralization; (3) OS-EPS strongly reduces the 
proliferation of differentiating osteoblasts BMSCs cells. This proliferation inhibition was not 
due to an induction of apoptosis. These results suggest that OS-EPS reduces the proliferation 
and accelerates the osteoblastic differentiation, leading to strong inhibition of mineralized 
nodule formation that would be in favour of an increase of the bone resorption. However, 
these results cannot explain the effect observed in vivo. No significant difference in 
obsteoblast surface was found between OS-EPS-treated mice and age-matched control mice. 
18 
 
Although the explanation for these conflicting results is unclear, findings in a whole bone 
organ culture system are more likely to reflect events in vivo than those that occur in isolated 
osteoblast cultures. It is possible that this reflects the propensity of OS-EPS to bind to other 
critical growth factors, such as (1) bone morphogenetic protein (BMP). HS and chondroitine 
sulphate directly regulate the BMP-mediated differentiation of mesenchymal stem cells 
(hMSCs) into osteoblasts. BMPs, which have been shown to be heparin-binding proteins, 
induce osteoblast differentiation in hMSCs (Manton et al., 2007). The role of heparin in the 
biological activity of BMP remains unclear. Heparin inhibits the binding of BMP-2 to BMPR 
and subsequent mRNA expression of Runx2, as well as phosphorylation of Smad and MAPK 
signal transduction. Furthermore, heparin was found to suppress the differentiation of 
osteoblastic MC3T3-E1 cells treated with BMP-2 (Kanzaki et al., 2008). In contrast, Zhao et 
al (2006) showed that heparin enhances BMP-induced osteoblast differentiation by protecting 
BMPs from degradation and inhibition by BMP antagonists; (2) tumor growth factor 1 
(TGF 1), a known inhibitor of osteoprogenitor growth, which has a higher affinity than 
several other bone-related, heparin-binding growth factors (Manton et al., 2006). This binding 
suggests that GAGs play a critical role in regulating TGF-  availability. Overcoming such 
sugar-mediated inhibition may prove important for wound repair. Given the importance of 
“heparin like” exopolysaccaharide for bone metabolism, it can be anticipated that OS-EPS 
due to its structural similarity with HS chains somehow interferes with the biological 
activities of these cell surface- and extracellular matrix-associated molecules. Taken together, 
these data show different levels of bone resorption regulation by GAGs or 
exopolysaccharides, most of them leading to proresorptive effects.  
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Materials and methods 
Materials.  Human M-CSF, human RANK and human OPG were obtained from R&D 
Systems (Abington, UK). Human RANKL was kindly provided by Amgen Inc. (Thousand 
Oaks, USA). Heparin sodium salt, heparan sulphate from bovine kidney, heparan sulphate 
from porcine intestinal mucosa, chondroitin sulphate from shark cartilage, dermatan sulphate 
from porcine intestinal mucosa and hyaluronic acid were purchased from Sigma (St Quentin 
Fallavier, France). 
The two low molecular weight exopolysaccharides (EPS and OS-EPS) were obtained 
from high molecular weight exopolysaccharide by previously described procedures (Colliec-
Jouault et al., 2001; Guezennec et al., 1998; Raguennes et al., 1997). EPS and OS-EPS are 
homogenous fractions with an average molecular mass of 13 kDa and 24 kDa, and 10% and 
40% sulphate groups, respectively, as determined by analytical high performance size-
exclusion chromatography (Colliec-Jouault et al., 2001). 
 
Culture medium and preparation of BMSCs. BMSCs were isolated from the bone marrow of 
4 week-old Sprague-Dawley rats (Janvier, Le Genest Saint Isle, France). After anesthetization 
and cervical dislocation, femurs and tibias were dissected aseptically and cleaned of soft 
tissues. BMSCs were then flushed out with a syringe fitted with a 22-gauge needle containing 
maintenance media (MM) consisting of α-Minimal Essential Medium (α-MEM, Invitrogen) 
supplemented with 10% fetal calf serum (FCS) and 1% antibiotics (100 U/mL penicillin and 
100 mg/L streptomycin). After centrifugation (5 minutes at 1600 rpm) cells were resuspended 
in 20 mL of MM. For osteogenic media (OM) culture conditions, this media was 
supplemented with 50 μg/mL ascorbic acid (Sigma) and 10
-8
 M dexamethasone (Sigma). 
Cells between passages 0 and 3 were used for all experiments. Cells were maintained at 37°C 
in a humidified atmosphere containing 5% CO2. 
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Proliferation of BMSCs. Cells were plated (5x10
4
/well) into a 6-well plate in MM overnight. 
Then MM was replaced by fresh OM in the presence or absence of 25 μg/mL EPS or OS-
EPS, and cells were left to recover for 7 days (media was changed every 3 days). Then, cells 
in each well were washed three times in 1x Dulbecco phosphate-buffered saline (DPBS), 
trypsinized and counted in triplicate at day 3 and 7 by using blue trypan exclusion dye. 
 
Induction of apoptosis. Programmed cell death was monitored microscopically following 
Hoechst staining. BMSCs were seeded at 10
4
 cells/well in a 24-well plate and cultured for 24 
h in MM. Then MM was replaced by fresh OM in the presence of 25 µg/mL OS-EPS for 24, 
48, and 72 h or 100 nM staurosporine (Sigma) for 16 h as a positive control. At the end of the 
culture period, cells were stained with 10 µg/ml Hoechst reagent for 30 min at 37°C, and then 
observed under UV microscopy (DMRXA; Leica, Wetzlar, Germany). 
Induction of apoptosis was also investigated by cleavage of caspase-3 substrates in 
supernatants of cultures with or without OS-EPS treatment. BMSCs were seeded at 15x10
3
 
cells/well (in a 24-well plate), then incubated with OS-EPS (25 µg/mL) for 24, 48, and 72 h. 
Cells incubated with 1 µM staurosporine for 6 h were used as positive controls. At the end of 
the incubation period, the cells were lysed with 50 µl of RIPA buffer for 30 min. The cells 
were then scraped off and protein content was quantified in parallel samples using the BCA 
(bicinchominique acid + Copper II sulphate) assay. Caspase-3 activity was assessed in 10 µl 
of the cell lysate with the kit CaspACEi Assay System (Fluorometric, Promega, Madison, 
USA) following the manufacturer’s instructions. 
 
Time-lapse microscopy. BMSCs were plated (2x10
3 
cells/well) in triplicate into a 24-well 
plate in MM overnight. Then MM was replaced by fresh OM in the presence or absence of 25 
μg/mL EPS or OS-EPS. Immediately post-treatment, the cultured dishes were placed onto a 
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time-lapse instrument (Leica) designed to capture transmission-phase images every 10 min 
from multiwell plates. Images were taken and edited using the MetamorphTM software. Cell 
divisions were then manually scored.  
 
Cell cycle analysis. Cells were plated in triplicate (2x10
5
/well) into a 6-well plate in MM 
overnight. Then MM was replaced by fresh OM in the presence or absence of 25 μg/mL EPS 
or OS-EPS. After 48 h cells were trypsinized and centrifuged at 1600 rpm for 3 min. Cell 
pellets were fixed in 70% ice-cold ethanol for 30 min and then washed twice in 100µl of 
DPBS. Cells were incubated in phosphate-citrate buffer at room temperature for 30 min then 
in DPBS containing 0.12% Triton X-100, 0.12 mM EDTA and 100 µg/ml ribonuclease A at 
37ºC for 30 min. Cells were then centrifuged, washed twice and incubated in 50 µg/ml 
propidium iodide for 20 min at 4°C. Cell cycle distribution was analyzed by flow cytometry 
F500 (Beckman Coulter France) based on 2N and 4N DNA content using the MultiCycle 
software. 
 
Mineralization Assay. BMSCs were plated (3.5x10
6
 cells/well) in duplicate into a 24-
multiwell plate in MM. After 24 hours of culture, the supernatant (MM) containing the non-
adherent hematopoietic cells was removed. At confluence (72 h later), MM was replaced by 
OM (media was changed twice a week) in the presence of 25 μg/mL EPS or OS-EPS. After 1 
week of culture, OM was supplemented with 10 mM β-glycerophosphate (Sigma) for 2 weeks 
(media was changed twice a week) in presence or absence of 25 µg/ml EPS or OS-EPS added 
at different times of the culture period. Then, Alizarin red staining (Alfa Aesar) was used to 
detect the mineralized nodules formed in vitro. Cells were washed in DPBS and fixed in 70% 
ice-cold ethanol for 1 h. The ethanol was then removed, and the fixed cells were washed three 
times with distilled water and incubated with alizarin red (40 mM, pH 7.4) for 10 minutes at 
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room temperature. After staining, excessive dye was washed gently with running water. 
Calcification deposits typically stained red. All experiments were performed three times. 
 
Osteogenic differentiation Assay. BMSCs were plated (15x10
6 
cells/well) into a 6-multiwell 
plate in MM. After 24 hours of culture, the supernatant (MM) containing the non-adherent 
hematopoietic cells was removed. At confluence (72 h later), MM was replaced by OM in the 
presence of 25 μg/mL EPS or OS-EPS (media was changed twice a week). After 1 week of 
culture, OM was supplemented with 10 mM β-glycerophosphate for 2 weeks (media was 
changed twice a week). For RT-qPCR analysis, total RNA was isolated from osteogenic 
culture at different times using the NucleoSpin II kit (Macherey-Nagel). RNA (500 ng) was 
reversed-transcribed (RT) using ThermoSript System (Invitrogen). cDNA synthesis was 
performed using total RNA with oligo(dT) at 50°C for 1 h. qPCR was performed in triplicate 
for each sample by using 5 µl 2x SYBR Green Supermix buffer (Bio-Rad, Marnes la 
Coquette, France), 1 μl cDNA, 300 nM of each primer, and DEPC H2O to a final volume of 
10 µl. After denaturing of cDNA at 98ºC for 30 sec, amplification and fluorescence 
determination were carried out in two steps: denaturation at 95ºC for 15 sec, and annealing 
and extension at 60ºC for 30 sec. The detection of SYBR Green was performed at the process 
of annealing. The sequence of the primers used in PCR reactions are shown in Table 1. Cyc1 
cDNA as internal controls were used to normalize the data to determine the relative 
expression of the target genes. Polymerase chain reactions were carried out in 96-well plates 
using the Chromo4 System (Bio-Rad). 
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Gene  Gene (full name) Accesion N° Sequence  (5’  3’) 
ALP Alkalin phosphatase NM_013059.1 Forward:  aggggcaactccatttttg 
   
Reverse:    ttgtaaccaggcccgttg 
Runx2 runt-related transcription factor 2 NM_053470.1 Forward:  cacagagctattaaagtgacagtgg 
   
Reverse:    aacaaactaggtttagagtcatcaagc  
BSP Bone Sialoprotein NM_012587.2 Forward:  cctacttttatcctcctctgaaacg 
   
Reverse:  tcgccatctccattttcttc 
OC Osteocalcin NM_013414.1 Forward:  aagcgcatctatggcaccac 
   
Reverse:  tcgagtcctggagagtagcc 
Collα1 Alpha-1 type I collagen NM_053304.1 Forward:  catgttcagctttgtggacct 
   
Reverse:  gcagctgacttcagggatgt 
Cyc1 cytochrome c-1 NM_001130491.1 Forward:  tgctacacggaggaagaagc 
   
Reverse:  atcctcattagggccatcct 
 
Differentiation of human CD14
+ 
cells into osteoclasts. Human peripheral blood mononuclear 
cells (PBMCs) were isolated by centrifugation over Ficoll gradient (Sigma Chemicals Co., St. 
Louis, MO). CD14
+
 cells were magnetically labeled with CD14 Microbeads and positively 
selected by MACS technology (Miltenyi Biotec, Bergisch Gladbach, Germany). CD14
+
 cells 
were plated (45x10
3 
cells/well) in triplicate into a 96-well plate in α-MEM containing 10% 
FCS and 25 ng/ml human M-CSF. After 3 days of culture, media was changed with fresh 
medium containing 10% FCS, 25 ng/ml human M-CSF, with or without 100 ng/ml hRANKL. 
Then medium was changed every 4 days. The formation of osteoclasts occurred around 14 
days and was observed by tartrate-resistant acid phosphatase (TRAP) staining. In this 
experiment, EPS or OS-EPS were added at different times of the culture period. Then, 
multinucleated cells (>3 nuclei) were counted under a light microscope (Leica DM IRB, 
Nanterre, France; Camera: Olympus D70, Analysis software: Olympus DP 
Controller/Manager, Hamburg, Germany) after TRAP staining (Sigma, Saint Quentin-
Fallavier, France) 
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Differentiation from the murine RAW 264.7 monocytic cell line. Murine RAW 264.7 
monocytic cells (ATCC, Promochem, Molsheim, France) were cultured in phenol red-free -
Minimal Essential Medium ( -MEM) (Invitrogen, Eragny, France) supplemented with 10% 
fetal calf serum (FCS) (Perbio, Logan, USA) and 1% non essential amino acids (Invitrogen). 
To induce osteoclast formation, RAW 264.7 cells were scraped then incubated at 37°C for 2 
minutes to allow adherence of the more differentiated cells. Non-adherent cells were then 
seeded in fresh medium at a density of 3x10
3
 cells/well in a 96-well plate. After 2 hours of 
culture, the medium was changed for fresh medium containing 100 ng/ml hRANKL with or 
without 0,5 µg/ml EPS or OS-EPS. The cells were stained histochemically for TRAP and the 
number of TRAP-positive multinuclear cells (MNCs) containing 3 or more nuclei was 
counted.  
 
Adherence of human CD14
+ 
cells. Cells were plated (25x10
4 
cells/well) in triplicate into a 96-
well plate in α-MEM containing 10% FCS and 25 ng/ml human M-CSF during 3 days (time 
required for these cells to adhere). The medium was then replaced with fresh medium 
containing α-MEM, 10% FCS and 25 ng/ml human M-CSF in the presence of 1 µg/ml EPS or 
OS-EPS during 5 days (media were changed once). Then, non-adherent cells in the supernant 
were counted in triplicate by using blue trypan exclusion dye. The adherent cells were washed 
three times in DPBS, trypsinized and counted as above. 
 
Surface plasmon resonance-binding assays. Experiments were carried out on a BIAcore 3000 
instrument (BIAcore). RANKL, OPG (5 µg/ml in 10 mM acetate buffer, pH 4.0 and pH 5.0 
(1:1;v/v)) and RANK (10 µg/ml in 10 mM acetate buffer, pH 5.0) were covalently 
immobilized to the dextran matrix of a CM5 sensor chip (BIAcore) via its primary amino 
groups at a flow rate of 30 µl/min. Immobilization levels ranging of 4000 resonance units 
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(RU) (RANKL and OPG) and 5000 RU (RANK) were obtained. EPS and OS-EPS KD values 
for OPG, RANK and RANKL were determined using single cycle kinetics, starting with 1 nM 
OS-EPS or 100nM EPS (OPG), 250 nM OS-EPS or 2 µM EPS (RANKL) and 100 nM OS-
EPS or 2 µM EPS (RANKL), then 1⁄2 dilutions. For binding analysis over the immobilized 
RANKL, OPG or RANK chip, the concentrations of 1 µg/ml OPG, 2 µg/ml RANK, 0.5 µg/ml 
RANKL, 20µM  GAGs (heparin, or heparan sulphate, or chondroitin sulphate, or dermatan 
sulphate, or hyaluronic acid), 20 µM EPS and 200 nM OS-EPS were used. Binding assays 
were performed at 25ºC in 10 mM Hepes buffer, pH 7.4, containing 0.15 M NaCl and 0.005% 
P20 surfactant (HBS-P buffer, BIAcore) at a flow rate of 30 µl/min. Control sensorgrams 
(flow cell without RANKL, OPG and RANK) were automatically subtracted from the 
sensorgrams obtained with immobilized RANKL or OPG or RANK to yield true binding 
responses. The resulting sensorgrams were fitted using BiaEval 4.1 software (BIAcore).  
 
Animal studies. twenty four 4-week-old male C3H/HeN male mice (Janvier, Le Genest Saint 
Isle, France) were housed under pathogen-free conditions at the Experimental Therapy Unit 
(Medicine Faculty of Nantes, France) in accordance with the institutional guidelines of the 
French Ethical Committee and under the supervision of authorized investigators. After 7 days 
of acclimatization these animals were assigned randomly to four groups: control (CT), heparin 
(Sigma H4784, 140U/mg, 50mg/ml), EPS and OS-EPS. All mice received (6 mg/kg) daily s.c. 
injection for a period of 28 days, consistent with the period of rapid growth in young mice. 
The 29
th
 day, these animals were anesthetized with isoflurane (0.2% air, delivered via 
nosecone) and sacrificed by cervical dislocation. Bilateral femurs of each animal were 
dissected for histological studies and microarchitectural parameter quantification. Two 
independent experiments were performed. 
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Histological analysis. After sacrifice, left femur were cleaned from adjacent tissues and fixed 
in 10% buffered formaldehyde. Then samples were decalcified in 4% EDTA 0.2% 
paraformaldehyde (pH 7.4) buffer for 4 weeks and embedded in paraffin wax for TRAP and 
ALP staining. Five-µm-thick sections were cut through the femur (microtome: Leica SM 
2500; Leica Instruments GmbH) and mounted on glass slides. Analysis and quantification of 
osteoblastic and osteoclastic areas were done using a Leica Q500 image analysis system. 
 
Micro-computed tomography (µCT). After sacrifice, the right femur from each animal was 
dissected of soft tissues, fixed in 10% buffered formaldehyde and the distal metaphysis was 
used for micro-computed tomography (μ-CT) on a SkyScan-1072 (SkyScan, Aartselaar, 
Belgium). CT-Analyser software (from SkyScan) was used to analyse the structure of the 
sample, using the global segmentation method. Two-dimensional (2D) images were used to 
generate three-dimensional (3D) reconstructions and to calculate morphometric parameters 
with the SkyScan CtAn 3D creator software supplied with the instrument. Analysis was 
performed for the trabecular bone, whereby the trabecular region was precisely contoured in 
each single cross section manually. Bone volume ratio (BV/TV), trabecular thickness (Tb.Th), 
trabecular number (Tb.N) and trabecular space (Tb.Sp) were assessed. 
 
Statistical analysis. All analyses were performed using GraphPad InStat v3.02 software (La 
Jolla, CA). The mean ± SD was calculated for all conditions and compared by ANOVA. In 
vivo experimentation results were analyzed with the unpaired nonparametric Mann–Whitney 
U test using two-tailed P-values. Differences relative to a probability of two-tailed p < 0.05 
were considered significant. 
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Figure Legends 
 
Figure 1: Branched nonasaccharidic repetitive unit of native EPS.  
 
Figure 2: OS-EPS inhibits BMSCs proliferation during osteoblastic differentiation. 
BMSCs were incubated in osteogenic media in the presence of 25µg/ml EPS or OS-EPS. 
After 7 days, images of treated cells were taken under light microscopy (A) and the number of 
viable cells was determined by trypan blue counting (*: p< 0.01) (B). Cumulative mitosis of 
the first 48h of incubation with of EPS or OS-EPS were manually scored from time-lapse 
analysis (C). Cell cycle distribution of BMSCs incubated with EPS or OS-EPS for 48 h was 
analyzed by propidium iodide staining and FACS analysis (D).  
  
Figure 3: OS-EPS inhibits the extracellular matrix mineralization from BMSCs in a 
dose-dependent manner. (A) BMSCs were incubated in osteogenic media for three weeks in 
the presence or absence of increased concentrations of EPS and OS-EPS. (B) EPS or OS-EPS 
at 25µg/ml were added at different times of the culture period as indicated. At the end of the 
culture period, Alizarin Red staining was performed (original magnification x 10). (C) Gene 
expression profiles of bone-specific markers of osteoblastic differentiation were determined 
by qPCR in absence (CT) or in presence of different OS-EPS concentration, The data 
represent fold difference in expression following normalization against Cyc1. 
 
Figure 4: OS-EPS inhibits RANKL-induced osteoclatogenesis and cell adhesion of 
human CD14
+
 monocytes. (A) CD14
+
 purified monocytes were first cultured for 3 days in 
25 ng/ml hM-CSF to achieve a complete cell adhesion. For osteoclastogenesis experiments, 
cells were then incubated for 15 days in the presence of 25 ng/ml hM-CSF with or without 
hRANKL (100 ng/ml). EPS or OS-EPS (0,5µg/ml) were added at different time points during 
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the culture period, as indicated: -3 days indicates the culture condition with only 25 ng/ml of 
hM-CSF (cellular adhesion period); 0 14 days indicate the period with 25 ng/ml of hM-CSF 
and 100 ng/ml of RANKL (Osteoclastic differentiation period). At the end of the culture 
period, TRAP staining was performed (original magnification x 40) and TRAP
 
positives 
multinucleated cells (more than 3 nuclei) were counted under a light microscope. (B) For 
adherence experiments, cells were incubated for 5 days in the presence of EPS or OS-EPS at 
1µg/ml. The non-adherent cells in the supernant were counted in triplicate by using blue 
trypan exclusion dye. The adherent cells were washed three times in 1x Dulbecco phosphate-
buffered saline (DPBS), trypsinised and counted as above. 
 
Figure 5: OS-EPS binds RANKL. Experiments were carried out on a BIAcore 3000 
instrument (BIAcore). GAGs (20µM), or EPS (20 µM), or OS-EPS (2µM) were injected at a 
flow rate of 30 μl/min over the immobilized-RANKL sensorchip (A). RANK (2µg/ml), or 
RANKL (0.5µg/ml) or OS-EPS (200nM) or OPG (1µg/ml) were injected at a flow rate of  30 
μl/min over the immobilized-RANKL sensorchip (B, D) or over the immobilized-RANK (C) 
or over the immobilized-OPG (E). EPS and OS-EPS KD values for immobilized OPG, RANK 
and RANKL were assessed (Table).  
 
Figure 6: OS-EPS facilitates the binding of RANK-RANKL. Real-time SPR binding 
analyses of interactions of RANK and RANKL pre-incubated or not with OS-EPS. 
Sensorgrams were recorded with RANKL (A) or RANKL pre-incubated with OS-EPS (B) 
immobilized on CM5 sensor chips, and injections of RANK solutions [50, 25, 12.5, 6.25, and 
3.125 nM RANK], using a BIAcore 3000 biosensor and BiaEval 4.1 software. The kinetic and 
thermodynamic values were ka (M
-1
s
-1
) = 5.28 10
5
; kd (s
-1
) = 1.27 10
-3
 and KD = 2.39 nM for 
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RANKL in (A), and ka (M
-1
s
-1
) = 1.23 10
6
; kd (s
-1
) = 1.32 10
-3
 and KD = 1.09 nM for RANKL 
pre-incubated with OS-EPS in (B). 
 
Figure 7: OS-EPS reduces trabecular bone. Twenty four 4-week-old male C3H/HeN male 
mice received daily s.c. injection of DPBS, EPS, OS-EPS or heparin (6 mg/kg) for a period of 
28 days. (A) Right femur of each animal was dissected for microarchitectural parameter 
quantification. The distal metaphysis were used for micro-computed tomography (μ-CT) on a 
SkyScan-1072 (SkyScan, Aartselaar, Belgium). µCT-Analyser software SkyScan was used to 
analyse the structure of the samples. Bone volume ratio (BV/TV), trabecular thickness 
(Tb.Th), trabecular number (Tb.N) and trabecular separation (Tb.Sp) were assessed (Table). 
(n= 6 by groups). (*: p< 0.05). (B) Analysis and quantification of osteoblastic and osteoclastic 
areas were done using a Leica Q500 image analysis system after TRAP and ALP staining, 
respectively. Two independent experiments were performed (n= 6 by groups). (*: p< 0.05). 
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Abstract 
 
The growth and differentiation of bone cells is controlled by various factors which can be 
modulated by heparan sulphates. Here, we investigated the effects of an oversulphated 
”heparin-like” exopolysaccharide (OS-EPS) on bone. We compared the effect of this 
compound with that of a native exopolysaccharide (EPS). Long-term administration of OS-
EPS causes cancellous bone loss in mice due, in part, to an increase in the number of 
osteoclasts lining the trabecular bone surface. No significant difference in cancellous bone 
volume was found between EPS-treated mice and age-matched control mice, underlying the 
importance of sulphatation in trabecular bone loss. However, the mechanism sustaining this 
osteoporosis was unclear. To clarify OS-EPS activities, we investigated the effect of OS-EPS 
in osteogenesis. Our results demonstrated that OS-EPS inhibited osteoclastogenesis in two 
cell models. By surface plasmon resonance technique we revealed that OS-EPS can constitute 
a hetero-molecular complex OS-EPS/RANKL/RANK and that RANK had a higher affinity 
for RANKL pre-incubated with OS-EPS than for RANKL alone which would be in favour of 
an increase in bone resorption.  However, in vitro, OS-EPS inhibit the early steps of osteoclast 
precursor adhesion and therefore inhibits the step of cell fusion. In addition, we showed that 
OS-EPS reduces the proliferation and accelerates osteoblastic differentiation, leading to 
strong inhibition of mineralized nodule formation, which would be in favour of an increase in 
bone resorption. Taken together, these data show different levels of bone resorption regulation 
by exopolysaccharides, most of them leading to proresorptive effects. 
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Introduction 
 
Bone, a specialized connective tissue, is continually remodelled according to 
physiological events. This remodelling results from the activities of many cell lineages 
including mainly osteoblasts, osteocytes and osteoclasts. Their cellular interactions control 
their cellular activities and the bone remodelling intensity. These interactions can be 
established either through a cell–cell contact or by the release of many polypeptidic factors 
and/or their soluble receptor chains (cytokines, growth factors). These factors can act directly 
on osteogenic cells and their precursors to control differentiation, formation and functions 
(e.g. matrix formation, mineralization, resorption) (Kwan Tat et al., 2004). Among these 
factors, proteoglycans (PGs) appear critical for maintaining an appropriate number of 
osteoblasts and osteoclasts by modulating their proliferation and/or differentiation 
(Lamoureux et al., 2007).  
PGs are composed of a core protein with covalently attached glycosaminoglycan 
(GAG) chains. These GAGs, linear polymers of repeated disaccharidic units, are sulphated 
and the number and position of sulphate are extremely variable in sulphated GAG depending 
on the tissular, cellular, and metabolic context, ensuring structural variability of these 
polysaccharides (Bernfield, 1999). These PGs are ubiquitous, being present as cell surface 
molecules anchored in the plasma membrane, as components of the insoluble extracellular 
matrix or as soluble molecules present in extracellular matrix and serum. PGs function in both 
cell–cell and cell–extracellular matrix adhesion and can also act to promote assembly of 
extracellular matrix molecules. Additionally, PGs bind a wide range of bioactive molecules, 
such as growth factors, chemokines, which regulate cell behaviour in normal and pathological 
processes. Thus, PGs or GAGs associated to the cell membrane or resident in the extracellular 
bone matrix regulated the bone growth and remodelling (Ruiz Velasco et al., 2010). 
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The osteoprotegerin (OPG)/Receptor Activator of NF- B (RANK)/RANK Ligand 
(RANKL) molecular triad has been identified as members of a ligand-receptor system that 
directly regulates osteoclast differentiation and osteolysis (Simonet et al, 1997). While 
RANKL is a powerful inducer of bone resorption through its interaction with RANK (Kong et 
al., 1999), OPG acts as a decoy receptor for RANKL, thereby strongly inhibiting osteoclast 
differentiation (Yasuda et al., 1998). Any dysregulation of their respective expression leads to 
pathological conditions (Wittrant et al., 2004). OPG contains a heparin-binding domain and 
strongly bind to GAGs with a high affinity (KD: 0.28 nM for heparin) (Theoleyre et al., 2006). 
Therefore, PGs decrease the bioavailability of OPG inducing its internalization (Standal et al., 
2002, Kwan Tat et al., 2006) are involved in OPG-induced chemotaxis of monocytes 
(Mosheimer et al., 2005) and enhance the RANKL  half-life at the cell membrane (Kwan Tat 
et al., 2006). Similarly to OPG, PGs interact with RANKL. For example, Shinmyouzu et al. 
(2007) showed that dermatan sulphate inhibits the binding of RANK to RANKL and reduce 
the RANKL-induced levels of MAPK signal transduction in osteoclast progenitors, thus 
abolishing osteoclastogenesis. These data demonstrate that PGs must be considered as 
essential co-factors modulating bone remodelling. Thus, PGs are not simply passive structural 
components of cells and extracellular matrices, rather, they are multifunctional molecules that 
regulate cell behaviour by fine tuning the function of many regulatory proteins (Lamoureux, 
2009). 
Heparin demonstrates several kinds of biological activities by binding to various 
extracellular molecules and plays pivotal roles in bone metabolism. However, the role of 
heparin in the biological activity of bone remains unclear. Recently, Ariyoshi et al. (2008) 
showed that heparin, after binding to RANKL, suppressed osteoclastogenesis and inhibited 
the formation of resorption pits induced by RANKL, whereas the other GAGs showed no 
effects. In contrast, Irie et al. (2007) showed that heparin specifically binds to OPG and 
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prevents OPG-mediated inhibition of osteoclastic bone resorption in the coculture of mouse 
bone marrow cells and osteoblasts and demonstrated that heparin enhances osteoclastic bone 
resorption by inhibiting OPG activity. Long-term heparin treatment causes cancellous bone 
loss in rats due in part to an increase in the number of osteoclasts lining the trabecular bone 
surface. However, results from various other groups suggest that GAGs, and in particular 
heparan sulphate (HS) and heparin, are potent co-stimulators of osteogenic signaling 
pathways (Zhao et al, 2006; Jackson et al, 2007; Ling et al, 2010)). Thus, the opportunity 
arises to leverage the stimulatory properties of HS-derived compounds as adjuvants for osteo-
inductive therapies.  
A broad series of polysaccharides has emerged as an important class of bioactive 
products (Franz and Alban, 1995; Bernas, 2003; Mayer and Lehmann, 2001). Polysaccharide-
producing marine microorganisms occur widely in nature in different types of habitat 
(Sutherland, 1996), and some thermophilic and mesophilic polysaccharide-producing strains 
have been isolated from deep-sea hydrothermal vents (Guezennec, 2002; Nichols et al., 
2005). Alteromonas infernus, classified as a non-pathogenic microorganism by the Institut 
Pasteur, secretes a water-soluble acidic heteropolysaccharide (Raguénès et al., 1997). The 
composition of this high-molecular-weight polysaccharide (10
6
 g/mol) differs in 
monosaccharide content and/or ratio and sulphate content (10%) from other polysaccharides 
isolated from deep-sea hydrothermal bacteria and from polysaccharides of other origins. 
Structural characterization has shown that this exopolysaccharide is a highly branched acidic 
heteropolysaccharide composed of neutral sugars (glucose, galactose) and uronic acids 
(glucuronic acid and galacturonic acid) (Roger et al, 2004). The high-molecular-weight 
exopolysaccharide was chemically depolymerised and sulphated, with a view to obtaining a 
bioactive compound compatible with a therapeutic use (Roger et al, 2004). Highly sulphated 
low molecular-weight exopolysaccharide (40% sulphate groups, MW: 24 000, Fig. 1), with 
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uronic acid and sulphate contents comparable to those of heparin, were obtained without 
altering the osidic composition of this polymer (Guezennec et al., 1998). In contrast to the 
exopolysaccharide secreted by Alteromonas infernus, this oversulphated exopolysaccharide 
(OS-EPS) exhibits anticoagulant properties. It is less potent than low-molecular-weight 
heparin and unfractionated heparin (2.5 and 6.5 times, respectively), and should therefore 
carry a lower risk of bleeding (Colliec-Jouault et al., 2001). OS-EPS increases angiogenic 
properties of FGF-2 (Fibroblast growth factors-2) or VEGF (Vascular endothelial growth 
factor), i.e. endothelial cell proliferation and differentiation into vascular tubes; however it 
also inhibits the effect of FGF-2-induced cell migration (Matou et al., 2005). These 
angiogenic properties of OS-EPS are related to its sulphate content because no effect was 
observed with the native low molecular-weight exopolysaccharide (EPS). FGFs play an 
important major role in the control of cell proliferation, differentiation, and survival in several 
tissues including bone (Marie, 2003). Notably, FGF2 was found to promote cell growth and 
osteoblast differentiation in bone marrow-derived mesenchymal cells (Miraoui et al, 2009). In 
addition, FGF2 upregulate the expression of RANKL on rheumatoid arthritis synovial 
fibroblasts (Nakano et al., 2004). However, no data concerning the structure and biological 
activity of these exopolysaccharides on bone cells proliferation and differentiation were 
available until now. To explore its capacity to promote bone resorption or formation, an 
influence of OS-EPS on bone cell proliferation and differentiation was determined. OE-EPS 
was compared with EPS in order to study the effect of sulphate content on the biological 
properties of the exopolysaccharide. 
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Results 
 
OS-EPS inhibits the proliferation of BMSCs during osteoblastic differentiation 
  To study the effect of OS-EPS on osteoblast precursors, we used the bone marrow 
stem cells (BMSCs) model, in which dexamethasone is known to induce osteoblast 
differentiation. Proliferation of BMSCs during osteoblastic differentiation was analyzed in the 
presence of OS-EPS. 25 µg/mL of OS-EPS significantly inhibited cell proliferation (Fig. 2A 
and 2B) in contrast to EPS. To determine whether these effects were due to inhibition of cell 
proliferation and/or induction of cell death, we used time-lapse microscopy to monitor the 
mitosis events. The results demonstrated a 70% inhibition of cell mitosis in the presence of 
25µg/mL of OS-EPS after   48 h of culture as compared to the control (Fig. 2C). To determine 
whether the OS-EPS induced death in BMSCs by apoptosis, Hoechst staining and caspase-3 
activation were investigated. Hoechst staining showed no modification of nuclear morphology 
in the presence of OS-EPS as compared to control cells (data not shown). Concerning the 
caspase-3 activity in BMSCs, the results showed that OS-EPS does not induce any activation 
of caspases (not shown). Flow cytometry of DNA content was performed to identify cell cycle 
perturbations following treatment with OS-EPS over a 48-h period in BMSCs. Although 24 h 
of OS-EPS treatment did not modulate the cell cycle in BMSCs (data not shown), 48 h of OS-
EPS treatment induced a cell cycle arrest in G1 phases (Fig. 2D).  Indeed, the number of cells 
in G1 phases increased from 73 ± 2 to 83 ± 3 % when treated with OS-EPS (Fig. 2D). This 
observation was concomitant with a reduction of cells in S and G2/M phases: 25 ± 3 versus 17 
± 2 % (Fig. 2D). EPS had no effect in any of the experimental conditions, underlying the 
importance of sulphatation in the proliferation. 
 
OS-EPS inhibits mineralized nodule formation in pre-osteoblasts 
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To examine the role of OS-EPS on extracellular matrix mineralization in BMSCs 
cultures, BMSCs were treated for 17 days with OS-EPS, after which mineral was visualized 
by von Kossa staining. As demonstrated in Fig. 3A, OS-EPS dose-dependently inhibited 
mineralization with maximal inhibition occurring at 50 µg/mL. In late BMSCs culture, OS-
EPS reduced the formation of bone nodules. To further understand the mechanism by which 
OS-EPS inhibits mineralization, cultures were treated with 25 µg/mL OS-EPS during days 3–
17. OS-EPS reduced the formation of bone nodules when added in the two first weeks but not 
later (Fig. 3B), suggesting that OS-EPS blocks culture mineralization mainly by adversely 
affecting osteoblast differentiation and matrix deposition during the early matrix assembly 
stage and not by direct binding to hydroxyapatite crystals during the mineralization stage. 
Based on reduced mineralization, it was expected that OS-EPS would reduce expression of 
osteoblastic markers in cells. This study was performed on BMSCs under conditions where 
runt-related transcription factor 2 (Runx2), alkaline phosphatase (ALP) and type I collagen 
expression (Col1 1) were observed by preosteoblast stage, followed by bone sialoprotein 
(BSP) and osteocalcin (OC) by mature osteoblast stage. Unexpectedly, after 17 days of 
treatment, OS-EPS induced BSP and OC in a dose dependent manner (Fig. 3C). In contrast, 
OS-EPS reduced ALP, Runx2 and coll 1 mRNA level in a dose dependent manner (Fig. 3C). 
However, Runx2 was transiently and strongly induced by OS-EPS; it increased after 7 days, 
reached a peak level at 10 days (14 days for the control), and decreased thereafter (Fig 3 C). 
This result clearly demonstrated an effect of OS-EPS on the osteoblastic differentiation. OS-
EPS acted at the early steps of the process by affecting the preosteoblast and accelerating the 
osteoblactic differentiation. 
 
OS-EPS inhibits RANKL-induced osteoclastogenesis in human models  
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CD14
+
 cells are human monocyte cells which can differentiate into tartrate-resistant acid 
phosphatase (TRAP)-positive multinucleated cells in 21 days upon RANKL stimulation. As 
shown in figure 4A, in contrast to EPS, addition of 0,5µg/ml OS-EPS, at the same time that 
RANKL addition, almost completely inhibited RANKL-induced osteoclastogenesis (p<0.01). 
We confirmed this effect in a second model of osteoclastogenesis. RAW 264.7 cells are 
murine monocyte/macrophage cells which can differentiate into TRAP-positive 
multinucleated cells in 5 days upon RANKL stimulation. OS-EPS completely inhibited 
RANKL-induced osteoclastogenesis of RAW 264.7 (results not shown). To better 
characterize the mechanisms by which OS-EPS inhibits osteoclast formation, the effect of 
OS-EPS were assessed at different times of the culture period. When OS-EPS was added 3 
days before RANKL (D-3) to the culture, no osteoclasts were generated after 17 days (Fig. 
4A) and the number of adherent CD14
+
 osteoclast precursors was decreased compared to the 
control condition. To determine whether these effects were due to induction of loss of 
adhesion, the effects of OS-EPS were evaluated by counting viable cells, as assessed by 
trypan blue exclusion. After the adherence of CD14
+
 cells in the wells, these cells were 
incubated with EPS or OS-EPS during 5 days. Blue trypan counting revealed that OS-EPS 
causes a loss of adherence of this type of cells (Fig. 4B). Thus in this culture condition, fewer 
osteoclast precursors adhered to the plastic surface and less osteoclasts were generated in the 
presence of RANKL. The addition of OS-EPS after one week culture step (D7) did not 
completely inhibit osteoclast formation (Figure 4A). OS-EPS acted at two distinct levels of 
osteoclastogenesis: i) at the early steps of the process by affecting and decreasing cell 
adherence and ii) at the end of the osteoclastogenesis process by inhibiting the spreading of 
the preformed osteoclasts. This result clearly demonstrated an effect of OS-EPS on RANKL-
induced osteoclastogenesis. OS-EPS acted at the early steps of the process by affecting and 
decreasing cell adherence. 
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OS-EPS binds to RANKL  
OPG/RANK and RANKL have been identified as members of a ligand-receptor 
system that directly regulates osteoclast differentiation and osteolysis. While RANKL is a 
powerful inducer of bone resorption through its interaction with RANK, OPG is a soluble 
decoy receptor and acts as a strong inhibitor of osteoclastic differentiation. 
Surface plasmon resonance (SPR)-binding assays showed that recombinant full length 
OPG binds immobilized heparin (Theoleyre et al., 2006). To determine the involvement of 
OS-EPS in the binding of OPG, we determined kinetic parameters by injecting different 
concentrations of OS-EPS over immobilized OPG and thus demonstrated a high-affinity OPG 
binding to OS-EPS (dissociation constant KD: 0.22 nM) (Fig. 5). To explore the molecular 
mechanism underlying the effect of OS-EPS on RANKL-induced osteoclastogenesis, we 
investigated the molecular interactions between RANKL and OS-EPS by SPR. Surprisingly, 
OS-EPS was also able to bind to immobilized-RANKL, whereas EPS was not (Fig. 5A). We 
next compared OS-EPS activity to that of heparin, heparan sulphate, chondroitin sulphate and 
dermatan sulphate. None of the GAGs analyzed were able to bind to RANKL, with the 
exception of OS-EPS (Fig. 5A). Furthermore, using a single cycle kinetic assay, the KD of 
OS-EPS for RANKL was 91 pM (Fig. 5).  
Since RANKL is the natural ligand of RANK, we wondered whether OS-EPS could 
inhibit the complex RANKL–RANK present at the osteoclast membrane. We investigated the 
molecular interactions between OS-EPS, RANKL and RANK by SPR technique. We 
confirmed that RANK or RANKL bound to immobilized RANKL or immobilized RANK, 
respectively (Fig. 5B and 5C). While, in our conditions, OS-EPS did not bind to immobilized 
RANK (Fig. 5C), it bound to the preformed RANKL/RANK complex (Fig. 5B) thereby 
forming a ternary complex OS-EPS/RANKL/RANK. In addition, the pre-incubation of OS-
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EPS (30 min at room temperature) with RANK or RANKL did not inhibit the capacity of OS-
EPS to further bind to the preformed ternary complex OS-EPS/RANKL/RANK (data not 
shown). However, sensorgrams with RANKL, pre-incubated or not with OS-EPS, 
immobilized on the surface of a CM5 sensor chip revealed different binding response units for 
RANK (Fig. 5B). To determine the biophysical binding parameters for the ternary complex 
interactions, real-time SPR spectroscopy was performed (Fig. 6). Surprisingly, the kinetic 
study shows a significant increase of the association rate of RANK to RANKL pre-incubated 
with OS-EPS facilitating the complex formation. RANK had higher affinity for RANKL pre-
incubated with OS-EPS surface sensor chips than for RANKL surface sensor chips (> 2-fold). 
This result would be in favour of an increase in bone resorption which has not been observed 
during the study of osteoclastogenesis (Fig. 4).  
RANKL is not only a ligand for RANK but also acts as ligand for the decoy receptor 
OPG. To determine whether or not OS-EPS could affect the complex OPG/RANKL, RANKL 
has been immobilized on a sensor chip, and the capacity of OS-EPS to bind to complex 
OPG/RANKL was analyzed. Similar to the RANKL/RANK complex, OS-EPS is able to bind 
to a preformed OPG–RANKL complex (Fig. 5D and 5E) forming another ternary complex 
OS-EPS/RANKL/OPG. Also, the pre-incubation of OS-EPS (30 min at room temperature) 
with OPG or RANKL did not inhibit the capacity of OS-EPS to further bind to the preformed 
ternary complex OS-EPS/RANKL/OPG (data not shown). However, no modification of the 
kinetic parameters of the interaction of the OPG to RANKL pre-incubated with OS-EPS was 
observed. 
 
OS-EPS induces trabecular bone loss.  
During the 28 days of this study all of the mice from the different treatment groups 
(OS-EPS, EPS and heparin-treated) gained weight. No significant differences with respect to 
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weight gain were found between those mice treated with either OS-EPS or EPS or heparin or 
age-matched controls. However, at the femur level, micro-CT scanner analysis revealed that 
the mouse femur was characterized by large remodelling activities as compared to control 
femurs (Fig.7A). Thus, OS-EPS produced a reduction in cancellous bone volume when 
compared with control. The effect of OS-EPS on cancellous bone was similar to that of our 
positive control (heparin). OS-EPS did not modify the cortical bone volume (data not shown) 
but significantly reduced the trabecular bone volume (p< 0.01; Fig.7A). The trabecular 
number (Tb.N) was significantly reduced by OS-EPS (p<0.05), whereas the trabecular space 
(Tb.Sp) increased (p<0.05). Trabecular thickness (Tb.Th) was not significantly altered (Fig. 
7). However, no significant difference in cancellous bone volume (BV/TV) was found 
between EPS-treated mice and age-matched control mice, underlying the importance of 
sulphatation in trabecular bone loss. 
Histologic sections were stained with TRAP or ALP to quantify osteoclast or 
osteoblast surface-based data, respectively. Figure 7B shows that the parameter of osteoblast 
surface was not significantly different when comparing OS-EPS or EPS-treated mice and age-
matched controls. In contrast, OS-EPS produced an increase in the percentage of cancellous 
bone covered by osteoclasts. Whereas mice given 6 mg/kg OS-EPS showed a 125% ± 23% 
(p<0.05) increase in osteoclast surface, osteoclast surface was unaffected by treatment with 
EPS (Fig. 7B). 
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Discussion 
 
In the present study, we have shown that long-term administration of OS-EPS, a 
`heparin-like' component (containing uronic acid and sulphate contents comparable to those 
of heparin) with `heparin-like' activity (anticoagulant properties), causes cancellous bone loss 
in mice due, in part, to an increase in the number of osteoclasts lining the trabecular bone 
surface. Our results are therefore similar to results published many years ago, in which long-
term administration of heparin was shown to lead to the development of osteoporosis (Muir et 
al., 1996). Similarly, Barbour et al.  (1994) showed that 36% of pregnant women undergoing 
long-term heparin treatment had a 10% reduction in femoral bone mineral density. Both 
heparin (Muir et al., 1996; Muir et al., 1997, Rajgopal et al., 2008) and OS-EPS increase the 
process of bone resorption. Although, heparin and OS-EPS has similar effects on osteoclast 
number, heparin was found to decrease osteoblast number (Muir et al., 1996; Muir et al., 
1997, Rajgopal et al., 2008), whereas OS-EPS has no effect. These effects resulting in bone 
loss begin early in the course of OS-EPS treatment (data not shown). However, the 
mechanism sustaining osteoporosis was unclear and it was difficult to determine if these 
effects on bone resorption were due to the direct effect of OS-EPS on osteoclasts or indirectly 
via its osteoblast activity. 
GAGs exhibit several kinds of biological activities by binding to various extracellular 
molecules and play a pivotal roles in bone metabolism. An indirect proof of heparan sulphate 
proteoglycans (HSPGs) involvement in osteoclast functions was recently shown in a 
publication that demonstrated that heparanase, a HS-degrading endoglycosidase expressed in 
osteoblastic cells, stimulates bone formation and bone mass (Kram et al., 2006). The effect of 
GAGs on osteoclastogenesis is controversial. For example, Ariyoshi et al.  (2008) and 
Shinmyouzu et al. (2007) showed an inhibition of osteoclastogenesis after a direct interaction 
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of GAGs with RANKL. In contrast, Irie et al. (2007) showed a stimulation of osteoclastic 
bone resorption by inhibiting OPG activity. Our results clearly demonstrated that OS-EPS 
inhibited osteoclastogenesis in two systems tested. Furthermore, we demonstrated the 
importance of the sulphation of the exopolysaccharide in their inhibitory effect. Sulphation 
also plays a key role in GAGs biological activities as revealed by the present work. Sulphated 
polysaccharides enhance the biological activity of both homodimers and heterodimers of bone 
morphogenetic protein (BMP) by continuously serving the ligands to their signalling receptors 
expressed on cell membranes, similar to oversulphated chondroitine sulphate that binds to 
BMP-4 and enhances osteoblast differentiation (Miyazaki et al., 2008). Sulphation has clearly 
been shown to participate in to the control of cell biology. Kumarasuriyar et al. (2009) 
showed that the chlorate-induced-desulphation of GAGs expressed by MG63 cells delayed in 
vitro osteogenesis. In addition, sulphation strongly modulates the interaction of GAGs with 
proteins such as growth factors or enzymes (Lamoureux et al., 2007; Gallagher, 2006).  
However, the question remains of how we can explain the strong discrepancies 
between the in vivo and in vitro results.  In this context, we first analyzed the interaction of 
OS-EPS with the OPG/RANK/RANKL molecular triad and the effect of OS-EPS on adhesion 
of osteoclast precursors. Here, we clearly showed that OS-EPS can constitute a hetero-
molecular complex (OS-EPS /RANKL/RANK or OS-EPS/RANKL/OPG) as demonstrated by 
surface plasmon resonance technique and that RANK possesses a higher affinity for RANKL 
pre-incubated with OS-EPS than for RANKL alone. Contrarily, OS-EPS does not interfere in 
the binding of RANKL by OPG. These results also revealed that RANKL had higher affinity 
for OS-EPS (KD = 91 pM) than for OPG (KD = 0.27 nM, Kwan Tat et al, 2006). In 
conclusion, the preferential binding of RANKL to OS-EPS is able to facilitate the binary OS-
EPS/RANKL complex formation, which, in turn, may facilitate the ternary OS-
EPS/RANKL/RANK complex formation, which would be in favour of an increase of the bone 
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resorption. Secondly, we analyzed the effects of OS-EPS on adhesion of osteoclast precursors, 
demonstrating a sequential effect of OS-EPS on RANKL-induced osteoclastogenesis. OS-
EPS inhibit the early step of osteoclast precursor adhesion and consequently inhibits the step 
of cell fusion. The alteration of cell adhesion and morphology prevents the cell fusion of 
osteoclast precursors and blocks osteoclast resorption which is particularly sensitive to cell 
morphology to develop their brush border (Rousselle and Heymann, 2002). 
Our data are in favour of a direct inhibitory activity of OS-EPS on osteoclastogenesis 
and the effect observed in vivo may be explained by its effects on the bone osteoblast 
compartment and then by the dysregulation of the balance between osteoblasts and osteoclasts 
or by a slow-down of bone remodeling. The rate of bone formation is dependent on the 
commitment and replication of osteoprogenitor cells, their differentiation into functional 
osteoblasts and the life span of mature osteoblasts. Cells are committed to the osteoblast 
lineage by induction of the transcription factor Runx2 (Karsenty, 2001). This osteoblast 
differentiation is regulated by the actions of systemic and local signalling factors. Among 
these factors are FGFs, a family of polypeptides that control the proliferation and 
differentiation of osteoblast cell (Xiao et al., 2010). Thus, FGF2 is a powerful promoter of 
bone growth, enhancing mineralized nodule formation (Downey et al., 2009). This effect is 
mediated via HSPGs that coordinate the interaction of FGFs with their high-affinity tyrosine 
kinase receptors, the FGFRs (Eswarakumar et al., 2005). The interaction of PGs with FGFs 
provides a physiological mechanism for regulation of FGF signalling, FGFR1, and the 
extracellular signal-regulated kinase pathway. Furthermore, osteoclast differentiation and 
activity are regulated by GAGs at different levels, as revealed in previous studies. FGF-2 
induces, after the binding to HS, the expression of RANKL and osteoclast maturation by 
rheumatoid synovial fibroblasts. FGF-2 not only augments the proliferation of rheumatoid 
synovial fibroblasts, but is also involved in osteoclast maturation, which leads to bone 
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destruction in rheumatoid arthritis (Nakano et al., 2004 Matou et al. (2005) showed the 
binding of OS-EPS to FGF-2, therefore we hypothesize that FGF-2 can induce bone 
resorption after binding to OS-EPS. 
Osteoblastic cells produce a complex extracellular matrix composed of a mixture of 
PGs, collagens and non-collagenous proteins. The interaction of PGs with matrix effector 
macromolecules via either their GAG chains or their protein core is critical in regulating a 
variety of cellular events. Alterations in the structural composition of the GAG/PG 
components of the extracellular matrix may have important consequences on cell proliferation 
and/or differentiation. Recently, Haupt et al. (2009) demonstrated the dependence of 
osteogenesis on specific HS chains, in particular those associated with glypican-3. The 
differentiating osteoblast-committed cells produce a homogenous HS species, which 
correlates with an increase in the HSPG glypican-3. Abrogation of glypican-3 reduces the 
expression of the osteogenic transcription factor Runx2. The data demonstrate tight linkage 
between HS modification and progression of osteogenic precursors through their 
developmental program.  
Our results showed that (1) OS-EPS reduces expression of ALP, coll I, Runx2 
(preosteoblast stage) in BMSCs cells and enhances OC and BSP mature osteoblast stage); (2) 
exogenous application of OS-EPS to cultures of primary BMSCs during in vitro 
differentiation completely blocks BMSC mineralization; (3) OS-EPS strongly reduces the 
proliferation of differentiating osteoblasts BMSCs cells. This proliferation inhibition was not 
due to an induction of apoptosis. These results suggest that OS-EPS reduces the proliferation 
and accelerates the osteoblastic differentiation, leading to strong inhibition of mineralized 
nodule formation that would be in favour of an increase of the bone resorption. However, 
these results cannot explain the effect observed in vivo. No significant difference in 
obsteoblast surface was found between OS-EPS-treated mice and age-matched control mice. 
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Although the explanation for these conflicting results is unclear, findings in a whole bone 
organ culture system are more likely to reflect events in vivo than those that occur in isolated 
osteoblast cultures. It is possible that this reflects the propensity of OS-EPS to bind to other 
critical growth factors, such as (1) bone morphogenetic protein (BMP). HS and chondroitine 
sulphate directly regulate the BMP-mediated differentiation of mesenchymal stem cells 
(hMSCs) into osteoblasts. BMPs, which have been shown to be heparin-binding proteins, 
induce osteoblast differentiation in hMSCs (Manton et al., 2007). The role of heparin in the 
biological activity of BMP remains unclear. Heparin inhibits the binding of BMP-2 to BMPR 
and subsequent mRNA expression of Runx2, as well as phosphorylation of Smad and MAPK 
signal transduction. Furthermore, heparin was found to suppress the differentiation of 
osteoblastic MC3T3-E1 cells treated with BMP-2 (Kanzaki et al., 2008). In contrast, Zhao et 
al (2006) showed that heparin enhances BMP-induced osteoblast differentiation by protecting 
BMPs from degradation and inhibition by BMP antagonists; (2) tumor growth factor 1 
(TGF 1), a known inhibitor of osteoprogenitor growth, which has a higher affinity than 
several other bone-related, heparin-binding growth factors (Manton et al., 2006). This binding 
suggests that GAGs play a critical role in regulating TGF-  availability. Overcoming such 
sugar-mediated inhibition may prove important for wound repair. Given the importance of 
“heparin like” exopolysaccaharide for bone metabolism, it can be anticipated that OS-EPS 
due to its structural similarity with HS chains somehow interferes with the biological 
activities of these cell surface- and extracellular matrix-associated molecules. Taken together, 
these data show different levels of bone resorption regulation by GAGs or 
exopolysaccharides, most of them leading to proresorptive effects.  
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Materials and methods 
Materials.  Human M-CSF, human RANK and human OPG were obtained from R&D 
Systems (Abington, UK). Human RANKL was kindly provided by Amgen Inc. (Thousand 
Oaks, USA). Heparin sodium salt, heparan sulphate from bovine kidney, heparan sulphate 
from porcine intestinal mucosa, chondroitin sulphate from shark cartilage, dermatan sulphate 
from porcine intestinal mucosa and hyaluronic acid were purchased from Sigma (St Quentin 
Fallavier, France). 
The two low molecular weight exopolysaccharides (EPS and OS-EPS) were obtained 
from high molecular weight exopolysaccharide by previously described procedures (Colliec-
Jouault et al., 2001; Guezennec et al., 1998; Raguennes et al., 1997). EPS and OS-EPS are 
homogenous fractions with an average molecular mass of 13 kDa and 24 kDa, and 10% and 
40% sulphate groups, respectively, as determined by analytical high performance size-
exclusion chromatography (Colliec-Jouault et al., 2001). 
 
Culture medium and preparation of BMSCs. BMSCs were isolated from the bone marrow of 
4 week-old Sprague-Dawley rats (Janvier, Le Genest Saint Isle, France). After anesthetization 
and cervical dislocation, femurs and tibias were dissected aseptically and cleaned of soft 
tissues. BMSCs were then flushed out with a syringe fitted with a 22-gauge needle containing 
maintenance media (MM) consisting of α-Minimal Essential Medium (α-MEM, Invitrogen) 
supplemented with 10% fetal calf serum (FCS) and 1% antibiotics (100 U/mL penicillin and 
100 mg/L streptomycin). After centrifugation (5 minutes at 1600 rpm) cells were resuspended 
in 20 mL of MM. For osteogenic media (OM) culture conditions, this media was 
supplemented with 50 μg/mL ascorbic acid (Sigma) and 10
-8
 M dexamethasone (Sigma). 
Cells between passages 0 and 3 were used for all experiments. Cells were maintained at 37°C 
in a humidified atmosphere containing 5% CO2. 
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Proliferation of BMSCs. Cells were plated (5x10
4
/well) into a 6-well plate in MM overnight. 
Then MM was replaced by fresh OM in the presence or absence of 25 μg/mL EPS or OS-
EPS, and cells were left to recover for 7 days (media was changed every 3 days). Then, cells 
in each well were washed three times in 1x Dulbecco phosphate-buffered saline (DPBS), 
trypsinized and counted in triplicate at day 3 and 7 by using blue trypan exclusion dye. 
 
Induction of apoptosis. Programmed cell death was monitored microscopically following 
Hoechst staining. BMSCs were seeded at 10
4
 cells/well in a 24-well plate and cultured for 24 
h in MM. Then MM was replaced by fresh OM in the presence of 25 µg/mL OS-EPS for 24, 
48, and 72 h or 100 nM staurosporine (Sigma) for 16 h as a positive control. At the end of the 
culture period, cells were stained with 10 µg/ml Hoechst reagent for 30 min at 37°C, and then 
observed under UV microscopy (DMRXA; Leica, Wetzlar, Germany). 
Induction of apoptosis was also investigated by cleavage of caspase-3 substrates in 
supernatants of cultures with or without OS-EPS treatment. BMSCs were seeded at 15x10
3
 
cells/well (in a 24-well plate), then incubated with OS-EPS (25 µg/mL) for 24, 48, and 72 h. 
Cells incubated with 1 µM staurosporine for 6 h were used as positive controls. At the end of 
the incubation period, the cells were lysed with 50 µl of RIPA buffer for 30 min. The cells 
were then scraped off and protein content was quantified in parallel samples using the BCA 
(bicinchominique acid + Copper II sulphate) assay. Caspase-3 activity was assessed in 10 µl 
of the cell lysate with the kit CaspACEi Assay System (Fluorometric, Promega, Madison, 
USA) following the manufacturer’s instructions. 
 
Time-lapse microscopy. BMSCs were plated (2x10
3 
cells/well) in triplicate into a 24-well 
plate in MM overnight. Then MM was replaced by fresh OM in the presence or absence of 25 
μg/mL EPS or OS-EPS. Immediately post-treatment, the cultured dishes were placed onto a 
21 
 
time-lapse instrument (Leica) designed to capture transmission-phase images every 10 min 
from multiwell plates. Images were taken and edited using the MetamorphTM software. Cell 
divisions were then manually scored.  
 
Cell cycle analysis. Cells were plated in triplicate (2x10
5
/well) into a 6-well plate in MM 
overnight. Then MM was replaced by fresh OM in the presence or absence of 25 μg/mL EPS 
or OS-EPS. After 48 h cells were trypsinized and centrifuged at 1600 rpm for 3 min. Cell 
pellets were fixed in 70% ice-cold ethanol for 30 min and then washed twice in 100µl of 
DPBS. Cells were incubated in phosphate-citrate buffer at room temperature for 30 min then 
in DPBS containing 0.12% Triton X-100, 0.12 mM EDTA and 100 µg/ml ribonuclease A at 
37ºC for 30 min. Cells were then centrifuged, washed twice and incubated in 50 µg/ml 
propidium iodide for 20 min at 4°C. Cell cycle distribution was analyzed by flow cytometry 
F500 (Beckman Coulter France) based on 2N and 4N DNA content using the MultiCycle 
software. 
 
Mineralization Assay. BMSCs were plated (3.5x10
6
 cells/well) in duplicate into a 24-
multiwell plate in MM. After 24 hours of culture, the supernatant (MM) containing the non-
adherent hematopoietic cells was removed. At confluence (72 h later), MM was replaced by 
OM (media was changed twice a week) in the presence of 25 μg/mL EPS or OS-EPS. After 1 
week of culture, OM was supplemented with 10 mM β-glycerophosphate (Sigma) for 2 weeks 
(media was changed twice a week) in presence or absence of 25 µg/ml EPS or OS-EPS added 
at different times of the culture period. Then, Alizarin red staining (Alfa Aesar) was used to 
detect the mineralized nodules formed in vitro. Cells were washed in DPBS and fixed in 70% 
ice-cold ethanol for 1 h. The ethanol was then removed, and the fixed cells were washed three 
times with distilled water and incubated with alizarin red (40 mM, pH 7.4) for 10 minutes at 
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room temperature. After staining, excessive dye was washed gently with running water. 
Calcification deposits typically stained red. All experiments were performed three times. 
 
Osteogenic differentiation Assay. BMSCs were plated (15x10
6 
cells/well) into a 6-multiwell 
plate in MM. After 24 hours of culture, the supernatant (MM) containing the non-adherent 
hematopoietic cells was removed. At confluence (72 h later), MM was replaced by OM in the 
presence of 25 μg/mL EPS or OS-EPS (media was changed twice a week). After 1 week of 
culture, OM was supplemented with 10 mM β-glycerophosphate for 2 weeks (media was 
changed twice a week). For RT-qPCR analysis, total RNA was isolated from osteogenic 
culture at different times using the NucleoSpin II kit (Macherey-Nagel). RNA (500 ng) was 
reversed-transcribed (RT) using ThermoSript System (Invitrogen). cDNA synthesis was 
performed using total RNA with oligo(dT) at 50°C for 1 h. qPCR was performed in triplicate 
for each sample by using 5 µl 2x SYBR Green Supermix buffer (Bio-Rad, Marnes la 
Coquette, France), 1 μl cDNA, 300 nM of each primer, and DEPC H2O to a final volume of 
10 µl. After denaturing of cDNA at 98ºC for 30 sec, amplification and fluorescence 
determination were carried out in two steps: denaturation at 95ºC for 15 sec, and annealing 
and extension at 60ºC for 30 sec. The detection of SYBR Green was performed at the process 
of annealing. The sequence of the primers used in PCR reactions are shown in Table 1. Cyc1 
cDNA as internal controls were used to normalize the data to determine the relative 
expression of the target genes. Polymerase chain reactions were carried out in 96-well plates 
using the Chromo4 System (Bio-Rad). 
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Gene  Gene (full name) Accesion N° Sequence  (5’  3’) 
ALP Alkalin phosphatase NM_013059.1 Forward:  aggggcaactccatttttg 
   
Reverse:    ttgtaaccaggcccgttg 
Runx2 runt-related transcription factor 2 NM_053470.1 Forward:  cacagagctattaaagtgacagtgg 
   
Reverse:    aacaaactaggtttagagtcatcaagc  
BSP Bone Sialoprotein NM_012587.2 Forward:  cctacttttatcctcctctgaaacg 
   
Reverse:  tcgccatctccattttcttc 
OC Osteocalcin NM_013414.1 Forward:  aagcgcatctatggcaccac 
   
Reverse:  tcgagtcctggagagtagcc 
Collα1 Alpha-1 type I collagen NM_053304.1 Forward:  catgttcagctttgtggacct 
   
Reverse:  gcagctgacttcagggatgt 
Cyc1 cytochrome c-1 NM_001130491.1 Forward:  tgctacacggaggaagaagc 
   
Reverse:  atcctcattagggccatcct 
 
Differentiation of human CD14
+ 
cells into osteoclasts. Human peripheral blood mononuclear 
cells (PBMCs) were isolated by centrifugation over Ficoll gradient (Sigma Chemicals Co., St. 
Louis, MO). CD14
+
 cells were magnetically labeled with CD14 Microbeads and positively 
selected by MACS technology (Miltenyi Biotec, Bergisch Gladbach, Germany). CD14
+
 cells 
were plated (45x10
3 
cells/well) in triplicate into a 96-well plate in α-MEM containing 10% 
FCS and 25 ng/ml human M-CSF. After 3 days of culture, media was changed with fresh 
medium containing 10% FCS, 25 ng/ml human M-CSF, with or without 100 ng/ml hRANKL. 
Then medium was changed every 4 days. The formation of osteoclasts occurred around 14 
days and was observed by tartrate-resistant acid phosphatase (TRAP) staining. In this 
experiment, EPS or OS-EPS were added at different times of the culture period. Then, 
multinucleated cells (>3 nuclei) were counted under a light microscope (Leica DM IRB, 
Nanterre, France; Camera: Olympus D70, Analysis software: Olympus DP 
Controller/Manager, Hamburg, Germany) after TRAP staining (Sigma, Saint Quentin-
Fallavier, France) 
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Differentiation from the murine RAW 264.7 monocytic cell line. Murine RAW 264.7 
monocytic cells (ATCC, Promochem, Molsheim, France) were cultured in phenol red-free -
Minimal Essential Medium ( -MEM) (Invitrogen, Eragny, France) supplemented with 10% 
fetal calf serum (FCS) (Perbio, Logan, USA) and 1% non essential amino acids (Invitrogen). 
To induce osteoclast formation, RAW 264.7 cells were scraped then incubated at 37°C for 2 
minutes to allow adherence of the more differentiated cells. Non-adherent cells were then 
seeded in fresh medium at a density of 3x10
3
 cells/well in a 96-well plate. After 2 hours of 
culture, the medium was changed for fresh medium containing 100 ng/ml hRANKL with or 
without 0,5 µg/ml EPS or OS-EPS. The cells were stained histochemically for TRAP and the 
number of TRAP-positive multinuclear cells (MNCs) containing 3 or more nuclei was 
counted.  
 
Adherence of human CD14
+ 
cells. Cells were plated (25x10
4 
cells/well) in triplicate into a 96-
well plate in α-MEM containing 10% FCS and 25 ng/ml human M-CSF during 3 days (time 
required for these cells to adhere). The medium was then replaced with fresh medium 
containing α-MEM, 10% FCS and 25 ng/ml human M-CSF in the presence of 1 µg/ml EPS or 
OS-EPS during 5 days (media were changed once). Then, non-adherent cells in the supernant 
were counted in triplicate by using blue trypan exclusion dye. The adherent cells were washed 
three times in DPBS, trypsinized and counted as above. 
 
Surface plasmon resonance-binding assays. Experiments were carried out on a BIAcore 3000 
instrument (BIAcore). RANKL, OPG (5 µg/ml in 10 mM acetate buffer, pH 4.0 and pH 5.0 
(1:1;v/v)) and RANK (10 µg/ml in 10 mM acetate buffer, pH 5.0) were covalently 
immobilized to the dextran matrix of a CM5 sensor chip (BIAcore) via its primary amino 
groups at a flow rate of 30 µl/min. Immobilization levels ranging of 4000 resonance units 
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(RU) (RANKL and OPG) and 5000 RU (RANK) were obtained. EPS and OS-EPS KD values 
for OPG, RANK and RANKL were determined using single cycle kinetics, starting with 1 nM 
OS-EPS or 100nM EPS (OPG), 250 nM OS-EPS or 2 µM EPS (RANKL) and 100 nM OS-
EPS or 2 µM EPS (RANKL), then 1⁄2 dilutions. For binding analysis over the immobilized 
RANKL, OPG or RANK chip, the concentrations of 1 µg/ml OPG, 2 µg/ml RANK, 0.5 µg/ml 
RANKL, 20µM  GAGs (heparin, or heparan sulphate, or chondroitin sulphate, or dermatan 
sulphate, or hyaluronic acid), 20 µM EPS and 200 nM OS-EPS were used. Binding assays 
were performed at 25ºC in 10 mM Hepes buffer, pH 7.4, containing 0.15 M NaCl and 0.005% 
P20 surfactant (HBS-P buffer, BIAcore) at a flow rate of 30 µl/min. Control sensorgrams 
(flow cell without RANKL, OPG and RANK) were automatically subtracted from the 
sensorgrams obtained with immobilized RANKL or OPG or RANK to yield true binding 
responses. The resulting sensorgrams were fitted using BiaEval 4.1 software (BIAcore).  
 
Animal studies. twenty four 4-week-old male C3H/HeN male mice (Janvier, Le Genest Saint 
Isle, France) were housed under pathogen-free conditions at the Experimental Therapy Unit 
(Medicine Faculty of Nantes, France) in accordance with the institutional guidelines of the 
French Ethical Committee and under the supervision of authorized investigators. After 7 days 
of acclimatization these animals were assigned randomly to four groups: control (CT), heparin 
(Sigma H4784, 140U/mg, 50mg/ml), EPS and OS-EPS. All mice received (6 mg/kg) daily s.c. 
injection for a period of 28 days, consistent with the period of rapid growth in young mice. 
The 29
th
 day, these animals were anesthetized with isoflurane (0.2% air, delivered via 
nosecone) and sacrificed by cervical dislocation. Bilateral femurs of each animal were 
dissected for histological studies and microarchitectural parameter quantification. Two 
independent experiments were performed. 
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Histological analysis. After sacrifice, left femur were cleaned from adjacent tissues and fixed 
in 10% buffered formaldehyde. Then samples were decalcified in 4% EDTA 0.2% 
paraformaldehyde (pH 7.4) buffer for 4 weeks and embedded in paraffin wax for TRAP and 
ALP staining. Five-µm-thick sections were cut through the femur (microtome: Leica SM 
2500; Leica Instruments GmbH) and mounted on glass slides. Analysis and quantification of 
osteoblastic and osteoclastic areas were done using a Leica Q500 image analysis system. 
 
Micro-computed tomography (µCT). After sacrifice, the right femur from each animal was 
dissected of soft tissues, fixed in 10% buffered formaldehyde and the distal metaphysis was 
used for micro-computed tomography (μ-CT) on a SkyScan-1072 (SkyScan, Aartselaar, 
Belgium). CT-Analyser software (from SkyScan) was used to analyse the structure of the 
sample, using the global segmentation method. Two-dimensional (2D) images were used to 
generate three-dimensional (3D) reconstructions and to calculate morphometric parameters 
with the SkyScan CtAn 3D creator software supplied with the instrument. Analysis was 
performed for the trabecular bone, whereby the trabecular region was precisely contoured in 
each single cross section manually. Bone volume ratio (BV/TV), trabecular thickness (Tb.Th), 
trabecular number (Tb.N) and trabecular space (Tb.Sp) were assessed. 
 
Statistical analysis. All analyses were performed using GraphPad InStat v3.02 software (La 
Jolla, CA). The mean ± SD was calculated for all conditions and compared by ANOVA. In 
vivo experimentation results were analyzed with the unpaired nonparametric Mann–Whitney 
U test using two-tailed P-values. Differences relative to a probability of two-tailed p < 0.05 
were considered significant. 
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OC: Ostéocalcin 
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Figure Legends 
 
Figure 1: Branched nonasaccharidic repetitive unit of native EPS.  
 
Figure 2: OS-EPS inhibits BMSCs proliferation during osteoblastic differentiation. 
BMSCs were incubated in osteogenic media in the presence of 25µg/ml EPS or OS-EPS. 
After 7 days, images of treated cells were taken under light microscopy (A) and the number of 
viable cells was determined by trypan blue counting (*: p< 0.01) (B). Cumulative mitosis of 
the first 48h of incubation with of EPS or OS-EPS were manually scored from time-lapse 
analysis (C). Cell cycle distribution of BMSCs incubated with EPS or OS-EPS for 48 h was 
analyzed by propidium iodide staining and FACS analysis (D).  
  
Figure 3: OS-EPS inhibits the extracellular matrix mineralization from BMSCs in a 
dose-dependent manner. (A) BMSCs were incubated in osteogenic media for three weeks in 
the presence or absence of increased concentrations of EPS and OS-EPS. (B) EPS or OS-EPS 
at 25µg/ml were added at different times of the culture period as indicated. At the end of the 
culture period, Alizarin Red staining was performed (original magnification x 10). (C) Gene 
expression profiles of bone-specific markers of osteoblastic differentiation were determined 
by qPCR in absence (CT) or in presence of different OS-EPS concentration, The data 
represent fold difference in expression following normalization against Cyc1. 
 
Figure 4: OS-EPS inhibits RANKL-induced osteoclatogenesis and cell adhesion of 
human CD14
+
 monocytes. (A) CD14
+
 purified monocytes were first cultured for 3 days in 
25 ng/ml hM-CSF to achieve a complete cell adhesion. For osteoclastogenesis experiments, 
cells were then incubated for 15 days in the presence of 25 ng/ml hM-CSF with or without 
hRANKL (100 ng/ml). EPS or OS-EPS (0,5µg/ml) were added at different time points during 
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the culture period, as indicated: -3 days indicates the culture condition with only 25 ng/ml of 
hM-CSF (cellular adhesion period); 0 14 days indicate the period with 25 ng/ml of hM-CSF 
and 100 ng/ml of RANKL (Osteoclastic differentiation period). At the end of the culture 
period, TRAP staining was performed (original magnification x 40) and TRAP
 
positives 
multinucleated cells (more than 3 nuclei) were counted under a light microscope. (B) For 
adherence experiments, cells were incubated for 5 days in the presence of EPS or OS-EPS at 
1µg/ml. The non-adherent cells in the supernant were counted in triplicate by using blue 
trypan exclusion dye. The adherent cells were washed three times in 1x Dulbecco phosphate-
buffered saline (DPBS), trypsinised and counted as above. 
 
Figure 5: OS-EPS binds RANKL. Experiments were carried out on a BIAcore 3000 
instrument (BIAcore). GAGs (20µM), or EPS (20 µM), or OS-EPS (2µM) were injected at a 
flow rate of 30 μl/min over the immobilized-RANKL sensorchip (A). RANK (2µg/ml), or 
RANKL (0.5µg/ml) or OS-EPS (200nM) or OPG (1µg/ml) were injected at a flow rate of  30 
μl/min over the immobilized-RANKL sensorchip (B, D) or over the immobilized-RANK (C) 
or over the immobilized-OPG (E). EPS and OS-EPS KD values for immobilized OPG, RANK 
and RANKL were assessed (Table).  
 
Figure 6: OS-EPS facilitates the binding of RANK-RANKL. Real-time SPR binding 
analyses of interactions of RANK and RANKL pre-incubated or not with OS-EPS. 
Sensorgrams were recorded with RANKL (A) or RANKL pre-incubated with OS-EPS (B) 
immobilized on CM5 sensor chips, and injections of RANK solutions [50, 25, 12.5, 6.25, and 
3.125 nM RANK], using a BIAcore 3000 biosensor and BiaEval 4.1 software. The kinetic and 
thermodynamic values were ka (M
-1
s
-1
) = 5.28 10
5
; kd (s
-1
) = 1.27 10
-3
 and KD = 2.39 nM for 
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RANKL in (A), and ka (M
-1
s
-1
) = 1.23 10
6
; kd (s
-1
) = 1.32 10
-3
 and KD = 1.09 nM for RANKL 
pre-incubated with OS-EPS in (B). 
 
Figure 7: OS-EPS reduces trabecular bone. Twenty four 4-week-old male C3H/HeN male 
mice received daily s.c. injection of DPBS, EPS, OS-EPS or heparin (6 mg/kg) for a period of 
28 days. (A) Right femur of each animal was dissected for microarchitectural parameter 
quantification. The distal metaphysis were used for micro-computed tomography (μ-CT) on a 
SkyScan-1072 (SkyScan, Aartselaar, Belgium). µCT-Analyser software SkyScan was used to 
analyse the structure of the samples. Bone volume ratio (BV/TV), trabecular thickness 
(Tb.Th), trabecular number (Tb.N) and trabecular separation (Tb.Sp) were assessed (Table). 
(n= 6 by groups). (*: p< 0.05). (B) Analysis and quantification of osteoblastic and osteoclastic 
areas were done using a Leica Q500 image analysis system after TRAP and ALP staining, 
respectively. Two independent experiments were performed (n= 6 by groups). (*: p< 0.05). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
